Synovial extracellular matrix specific chimeric antigen receptors for targeting regulatory t cells to treat autoimmune diseases
The specific binding of citrulline-based polypeptides by chimeric antigen receptor (CAR) solves the problem of difficulty in treating RA, significantly improves the activation and proliferation ratio of Treg cells, and demonstrates the therapeutic potential in the RA model.
Patent Information
- Application Number
- CN202411010159.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-06
- Filing Date
- 2022-07-29
- Publication Date
- 2024-12-03
AI Technical Summary
The prior art is difficult to effectively treat rheumatoid arthritis (RA), and traditional therapies have long-term side effects and high cost problems.
A chimeric antigen receptor (CAR) was developed that specifically recognizes and binds citrulline-lated polypeptides to post-translational modifications in synovial extracellular matrix in RA patients by engineering regulatory T cells (Tregs) Protein is targeted to regulate and inhibit inflammatory response.
It has achieved stronger responsiveness and inhibitory function to the citrulline protein in synovial fluid of RA patients, significantly improving the activation and proliferation ratio of Treg cells, and demonstrating the therapeutic potential in the RA model.
Smart Images

Figure CN119060200A_ABST
Abstract
Description
This invention application is a divisional application based on an invention patent application with an application date of July 29, 2022, application number 202280061407.8 (international application number PCT / US2022 / 074321), and name “Synovial extracellular matrix-specific chimeric antigen receptor for targeting regulatory T cells to treat autoimmune diseases”. CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 227,320, filed on July 29, 2021, and U.S. Provisional Application No. 63 / 339,361, filed on May 6, 2022, each of which is hereby incorporated by reference in its entirety. Reference to an electronic sequence listing
[0002] The contents of the electronic sequence listing (237752000340SEQLIST.xml; size: 50,843 bytes; and creation date: July 28, 2022) are incorporated herein by reference in its entirety. Technical Field
[0003] The present disclosure relates to chimeric antigen receptors reactive with citrullinated antigens and regulatory T cells expressing these receptors for use in treating autoimmune diseases. Background Art
[0004] Autoimmune diseases affect a large number of people. For example, rheumatoid arthritis (RA) is a chronic inflammatory disease that targets peripheral joints, leading to bone erosion, impaired mobility and reduced quality of life. It is affecting 0.5%-1% of the world's population, and the incidence continues to rise. The pathogenesis of RA is mainly located in the synovial joints, where immune cells composed of T cells, B cells, macrophages and dendritic cells infiltrate the synovium. In addition, fibroblast-like synoviocytes present in the synovial sub-layer proliferate and cause cartilage damage.
[0005] Synovial hyperplasia in rheumatoid arthritis leads to infiltration of the synovium by immune cells and subsequent cartilage damage and bone erosion.
[0006] There is currently no cure for RA, as well as many other autoimmune conditions. RA patients typically require lifelong treatment, which, in addition to being extremely expensive, can cause long-term and serious side effects, such as infection and risk of rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0007] The accompanying drawings, which are incorporated herein and form a part of the specification, illustrate exemplary embodiments and, together with the description, further serve to enable those skilled in the relevant art to make and use these embodiments and other embodiments that are apparent to those skilled in the art. The present invention will be described in more detail in conjunction with the following drawings, in which:
[0008] Figure 1 : Initial data containing the MND promoter and EGFRt backbone showed that the CV CARs BVCA1 and SBT01G had the strongest response to plate-bound full-length CV (n=2).
[0009] Figure 2 : Assays using soluble full-length CV show dose responses for CV CAR BVCA1 and SBT01G-HL only (n=1).
[0010] Figure 3 : Assays with soluble beads bound peptides demonstrate binding specificity (n=1).
[0011] Figure 4 : MND-SBT01G showed a stronger response to plate-bound, antibody-captured CV (but not soluble CV) than MND-BVCA1.
[0012] Figure 5 : Tests on the first synovial fluid from the innovative study showed that SBT01G had a stronger response than BVCA1.
[0013] Figure 6 Further testing of 15 synovial fluid samples from Swedish patients showed that SBT01G was more potent than BVCA1 in producing responses.
[0014] Figure 7 : Primary Treg responses to synovial fluid (SF) showed that SBT01G was more sensitive to SF from RA patients compared with BVCA1.
[0015] Figure 8 : SBT01G, but not BVCA1, was also able to respond to plate-bound full-length PAD2-citrullinated fibrinogen.
[0016] Fig. 9 SBT01G CAR and Treg as effectors responded to citrullinated fibrinogen, but BVCA1 did not.
[0017] Figure 10A-10B : Both EF1A and MND promoters showed functional responses of CV CAR to soluble bead-bound peptide. Therefore, CAR promoter does not affect Treg phenotype.
[0018] Fig.11 : The scFv linker has little effect on the function of SBT01G CAR-based.
[0019] Figure 12A-12B: SBT01G was expressed by a higher percentage of cells compared with BVCA1, but BVCA1 and SBT01G CAR-T cells had similar FoxP3 and Helios signatures.
[0020] Fig.13 CV-CAR Treg cells (SBT01G), but not non-transduced Treg cells, were activated by citrullinated vimentin (CV). Activation was demonstrated by target antigen-specific increases in proliferation, CD71 expression, and IL-10 secretion.
[0021] Fig.14 : CV-CAR Treg cells respond to citrullinated proteins in the synovial fluid from most RA patients. In contrast, CV-CAR Treg cells do not respond to synovial fluid from normal controls (subjects without RA).
[0022] Fig.15 : CV-CAR Treg cells (SBT01G) from two donors, but not untransduced Treg cells, were specifically activated by synovial fluid from RA patients.
[0023] Figure 16A-16B : Evaluation of the suppressive function of CV-CAR Treg cells. Fig.16A It was shown that CV-CAR Treg cells were able to inhibit the proliferation of CD3 / CD28 pre-activated Teff cells in the presence (but not in the absence) of CV. Fig. 16B showed that CV-CAR Treg cells were able to inhibit the proliferation of CD19-CAR Teff cells in the presence of CV, while untransduced Treg cells could not.
[0024] Fig.17 :Shows the timeline of human CV-CAR Treg cell in vivo activation in a lipopolysaccharide (LPS)-induced murine lung inflammation model. Briefly, human CV-CAR Treg cells were administered intravenously (IV) on day 0, human IL-2 was administered intraperitoneally (IP) twice daily, and LPS was administered intranasally (IN) on days 0, 1, 6, and 12. On day 13, mice were sacrificed and organs were harvested to facilitate analysis of Treg cells.
[0025] Figure 18A-18B : Shown are flow cytometry dot plots comparing epidermal growth factor (EGFR) expression and CellTrace Violet (CTV) levels of human CV-CAR Treg cells. Fig.18A How to determine the proliferation ratio of CV-CAR Treg (EGFR+) is shown. Specifically, the proliferation ratio is equal to the % of EGFR+, CTV- cells divided by the % of EGFR+, CTV- cells. Fig.18B Shown is how to determine the fold change in EGFR ratio.
[0026] Figure 19A-19B : CV-CAR Tregs proliferate in an LPS-induced murine lung inflammation model but not in PBS control recipients. Fig.19A The absolute number of CD45+, CD3+ Tregs in the lungs of the various study groups is shown, and Fig.19B Shown are the proliferation rates of Tregs in the lungs of the various study groups. Summary of the invention
[0027] Regulatory T cells (Tregs) are defective in RA patients and mouse models. Therefore, Treg-based adoptive cell therapy (ACT) represents a promising approach for RA. In fact, Treg-based ACT reverses the disease in animal models of RA. In this study, antibodies isolated from RA patients were used to engineer CARs specific for citrullinated vimentin (CV) and other post-translationally modified proteins found in large quantities and almost exclusively in the synovial extracellular matrix (ECM) of affected joints.
[0028] Disclosed herein is a chimeric antigen receptor (CAR) that specifically recognizes antigens associated with autoimmune diseases. In particular, CAR can be specific to post-translationally modified antigens. In particular, CAR can specifically bind to citrullinated polypeptides, which include vimentin, citrullinated filaggrin, and citrullinated fibrinogen.
[0029] Chimeric antigen receptor (CAR) is engineered to specifically target post-translationally modified proteins (i.e., citrullinated vimentin, citrullinated filamentous protein, and citrullinated fibrinogen), which are expressed in the extracellular matrix of inflamed joints of patients with rheumatoid arthritis (RA). In some embodiments, the single-chain variable fragment (scFv) portion of CAR is obtained from an antibody that is highly specific to citrullinated proteins isolated from peripheral blood of RA patients. In one embodiment, a specific scFv chain is inserted into a second-generation CAR construct. In some embodiments, the scFv chain is inserted into a CAR construct cloned in a lentiviral vector. In a specific embodiment, unless otherwise indicated by the context, reference to antibodies is applicable to the antigen binding domains of the CAR of the present disclosure. DETAILED DESCRIPTION I. Definitions
[0030] Unless otherwise indicated, terminology and notation for biochemistry, nucleic acid chemistry, molecular biology, developmental biology, and molecular genetics follow that of standard conventions and textual materials in the field, such as Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed. (Cold Spring Harbor Press, 1989); Alberts and Singer, Developmental Biology, 8th ed. (Sinauer Associates Inc., Sunderland, MA, 2006); Kornberg and Baker, DNA Replication, 2nd ed. (WH Freeman, New York, 1992); Gaits, ed., Oligonucleotide Synthesis: A Practical Approach (IRL Press, Oxford, 1984); Lehninger, Biochemistry, 2nd ed. (Worth Publishers, New York, 1975); Eckstein, ed., Oligonucleotides and Analogs: A Practical Approach (Oxford University Press, New York, 1991); etc.
[0031] As used herein, the terms "antigen", "immunogen" and "antibody target" refer to a molecule, compound or complex that is recognized by an antibody (i.e., can be bound by an antibody). The term can refer to any molecule that can be recognized by an antibody, such as a polypeptide, a polynucleotide, a carbohydrate, a lipid, a chemical moiety or a combination thereof (e.g., a phosphorylated or glycosylated polypeptide, etc.). The skilled artisan will understand that the term does not indicate that a molecule is immunogenic in every context, but simply indicates that it can be targeted by an antibody.
[0032] As used herein, the term "epitope" refers to a local site on an antigen that is recognized and bound by an antibody. An epitope can include multiple parts of several amino acids or several amino acids, such as 5 or 6 or more (e.g., 20 or more) amino acids or multiple parts of those amino acids. In some cases, the epitope includes non-protein components, such as components from carbohydrates, nucleic acids, or lipids. In some cases, the epitope is a three-dimensional portion. Therefore, for example, in the case where the target is a protein, the epitope can be composed of continuous amino acids or amino acids from different parts of the protein approached by protein folding (e.g., discontinuous epitopes).
[0033] As used herein, the term "antibody" refers to a polypeptide comprising a framework region from an immunoglobulin gene that specifically binds and recognizes an antigen. Typically, the "variable region" contains the antigen binding region of an antibody (or its functional equivalent) and is the most critical in terms of specificity and affinity of binding. An exemplary immunoglobulin (antibody) structural unit comprises a tetramer. Each tetramer is composed of two pairs of identical polypeptide chains, each pair having a "light" chain (about 25 kD) and a "heavy" chain (about 50-70 kD).
[0034] Antibodies can be (i) any of the five major classes of immunoglobulins based on the identity of their heavy chain constant domains - α (IgA), δ (IgD), ε (IgE), γ (IgG), and μ (IgM), or (ii) a subclass (isotype) thereof (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2). The light chain can be λ or κ.
[0035] The following is a non-exhaustive list of different antibody formats that all retain antigen binding activity: (1) Complete immunoglobulin (also called “intact” antibody) (two light chains and two heavy chains, e.g., a tetramer); (2) immunoglobulin polypeptide (light chain or heavy chain); (3) Antibody fragments, such as Fv (monovalent or bivalent variable region fragments, and which may only contain the variable region (e.g., V L and / or V H ))、Fab(V L C L V H C H )、F(ab')2、Fv(V L V H ), scFv (single-chain Fv) (comprising V connected by a linker such as a peptide linker L and V H polypeptides), (scFv)2, sc(Fv)2, bispecific sc(Fv)2, bispecific (scFv)2, minibody (sc(FV)2 fused to a CH3 domain), diabody (non-covalent dimer of single-chain Fv (scFv) fragments consisting of heavy chain variable (VH) and light chain variable (VL) regions connected by a small peptide linker), triabody (trivalent sc(Fv)3 or trispecific sc(Fv)3); (4) multivalent antibodies (antibodies containing binding regions that bind to two different epitopes or proteins, such as “scorpion” antibodies); (5) fusion proteins comprising the binding portion of an immunoglobulin fused to another amino acid sequence (e.g., a fluorescent protein); and (6) Heavy chain-only antibodies or antibody fragments, which have only two heavy chains and lack the two light chains normally present in antibodies.
[0036] The generation and characterization of tandem scFvs and diabodies are described, e.g., in Asano et al. (2011) J Biol. Chem. 286: 1812; Kenanova et al. (2010) Prot Eng Design Sel 23: 789; Asano et al. (2008) Prot Eng Design Sel 21: 597.
[0037] As used herein, the phrase "CDR sequence set" refers to the three heavy chain and / or three light chain CDRs of a specific antibody described herein. A "light chain" CDR sequence set refers to the light chain CDR sequences. A "heavy chain" CDR sequence set refers to the heavy chain CDR sequences. A "complete" CDR sequence set refers to both the heavy chain and light chain CDR sequences. CDRs are predicted based on IMGT sequence alignments.
[0038] As used herein, the term "chimeric antibody" refers to an antibody having amino acid sequences derived from two or more species. In one embodiment, the variable regions of both the light and heavy chains correspond to the variable regions of an antibody with the desired specificity, affinity and capacity derived from one mammalian species (e.g., mouse, rat, rabbit, etc.), while the constant regions are homologous sequences derived from another species (typically in a subject receiving therapy, such as a human) to avoid eliciting an immune response.
[0039] As used herein, the term "humanized antibody" refers to a chimeric antibody in which the CDRs in the VH and VL regions of a non-human antibody with desired specificity, affinity and capacity are transplanted to human framework sequences. In one embodiment, the framework residues of a humanized antibody are modified to improve and optimize antibody specificity, affinity and capacity. Humanization (i.e., substitution of non-human CDR sequences for corresponding sequences of a human antibody) can be performed according to the methods described in, for example, U.S. Pat. Nos. 5,545,806; 5,569,825; 5,633,425; 5,661,016; Riechmann et al., Nature 332:323-327 (1988); Marks et al., Bio / Technolog 10:779-783 (1992); Morrison, Nature 368:812-13 (1994); Fishwild et al., Nature Biotechnology 14:845-51 (1996).
[0040] As used herein, the term "human antibody" refers to an antibody produced by humans or an antibody having an amino acid sequence corresponding to the antibody produced by humans prepared by any technique known in the art.
[0041] The specificity of binding can be defined based on the comparative dissociation constant (Kd) of an antibody (or other targeting moiety) for a target compared to the dissociation constants for the antibody and other materials in the environment or generally unrelated molecules. A larger (higher) Kd is a Kd describing a lower affinity interaction. Conversely, a smaller (lower) Kd is a Kd describing a higher affinity interaction or tighter binding. By way of example only, the Kd for antibody specific binding to a target can be femtomolar, picomolar, nanomolar, or micromolar, and the Kd for antibody binding to an unrelated material can be millimolar or higher. Binding affinity can be in the micromolar range (kD = 10 -4 Up to 10 -6 ), nanomolar range (kD = 10 -7 M to 10 -9 M), picomolar range (kD = 10 -10 M to 10 -12 M), or femtomolar (kD = 10 -13 M to 10 -15 M) inside.
[0042] As used herein, if the antibody is expressed at less than 10 -4 M (i.e., in the micromolar range) of Kd binding to an antigen or epitope, then it "binds" or "recognizes" an antigen or epitope. The term "binding" with respect to a cell type (e.g., an antibody that binds to a cancer cell) typically indicates that the agent binds to the majority of cells in a pure population of those cells. For example, an antibody that binds to a given cell type typically binds to at least 2 / 3 of the cells in a specified cell population (e.g., 67%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%). In some cases, binding to a polypeptide can be determined by comparing the binding of an antibody to cells presenting the polypeptide with the binding (or lack of binding) of the antibody to cells that do not express the polypeptide. Those skilled in the art will recognize that some variations will occur depending on the method and / or threshold for determining binding. The affinity of an antibody for a target can be determined according to methods known in the art (eg, as reviewed in Ernst et al., Determination of Equilibrium Dissociation Constants, Therapeutic Monoclonal Antibodies (Wiley & Sons ed. 2009)).
[0043] As used herein, the term "greater affinity" as used herein refers to the relative degree of antibody binding, wherein antibody X binds to target Y more strongly (Kon) than to target Z and / or has a smaller dissociation constant (Koff) than to target Z, and in this context, antibody X has a greater affinity for target Y than to Z. Likewise, the term "lesser affinity" herein refers to the degree of antibody binding, wherein antibody X binds to target Y less strongly than to target Z and / or has a larger dissociation constant than to target Z, and in this context, antibody X has a smaller affinity for target Y than to Z. The affinity of the binding between an antibody and its target antigen can be expressed as KA equals 1 / KD, where KD equals kon / koff. Surface plasmon resonance technology can be used (e.g., using the Molecular Affinity Screening System (MASS-1) (SierraSensors GmbH, Hamburg, Germany) to measure kon and koff values. Antagonists or blocking antibodies are antibodies that partially or completely block, inhibit or neutralize biological activity associated with the target antigen relative to activity under similar physiological conditions in the absence of the antibody. Antagonists can be competitive, non-competitive or irreversible. Competitive antagonists are substances that bind to the natural ligand or receptor at the same site as the natural ligand-receptor interaction or bind allosterically in a way that induces changes to prevent normal binding. Non-competitive antagonists bind at a different site than the natural ligand-receptor interaction, but reduce the KD or the signal generated by the interaction. Irreversible inhibitors cause covalent modification of the receptor, thereby preventing any subsequent binding.
[0044] As used herein, the term "avidity" refers to the overall stability of the binding complex between an antibody and a target antigen. It is controlled by three factors, which are (i) the intrinsic affinity of the antibody for the antigen, (2) the valence of the antibody, and (3) the geometric arrangement of the interacting components. Avidity is the strength of the interaction between an antibody and a single target, while avidity is the cumulative strength of multiple affinities. In one embodiment, the antibodies provided herein are bivalent.
[0045] As used herein, an antibody "preferentially binds" a first antigen relative to a second antigen if the antibody binds the first antigen with greater affinity than to the second antigen. Preferential binding can be any of at least 2-fold, 5-fold, 9-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 500-fold, or 1000-fold affinity.
[0046] As used herein, if the antibody is expressed at a concentration of at least 1 × 10 -6 M, 1×10 -7 M, 1×10 -8 M, 1×10 -9 M, 1×10 -10 M, 1×10-11 M, 1×10 -12 An antibody "specifically binds" or is "specific for" a target antigen or group of target antigens if it binds to each member of the target antigen or group of target antigens with an affinity greater than that of any of the M's and, for example, binds to each member of the target antigen or group of target antigens with an affinity at least twice that of the affinity for a compared non-target antigen. Typically, specific binding is characterized by binding to the antigen with sufficient affinity such that the antibody is useful as a diagnostic agent for detecting the antigen or epitope and / or as a therapeutic agent targeting the antigen or epitope.
[0047] As used herein, the term "polypeptide" refers to a molecule having a sequence of natural and / or non-natural amino acids linked by peptide bonds. The term "peptide" refers to a short polypeptide, typically no more than 30 amino acids in length. The amino acid sequence of a polypeptide is referred to as its "primary structure". The term "protein" refers to a polypeptide having a secondary, tertiary and / or quaternary structure (a structure stabilized, for example, by hydrogen bonds, relationships between secondary structures and structures formed by more than one protein). Proteins may be further modified by other attached moieties such as carbohydrates (glycoproteins), lipids (lipoproteins), phosphate groups (phosphoproteins), etc.
[0048] As used herein, an amino acid sequence "consists" only of the amino acids in that sequence.
[0049] As used herein, a first amino acid sequence "consists essentially of" a second amino acid sequence if the first amino acid sequence (1) comprises the second amino acid sequence and (2) is no more than 1, no more than 2, or no more than 3 amino acids longer than the second amino acid sequence.
[0050] As used herein, if the second amino acid sequence comprises the first amino acid sequence, the first amino acid sequence is a "fragment" of the second amino acid sequence. In certain embodiments, the first amino acid sequence, which is a fragment of the second amino acid sequence, may have no more than 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids less than the second amino acid sequence.
[0051] As used herein, a "functional equivalent" of a reference amino acid sequence is a sequence that is not identical to the reference sequence but contains minor changes (e.g., insertion, deletion, or substitution of one or several amino acids). A functionally equivalent sequence retains the function (e.g., immunogenicity) of the reference sequence to which it is equivalent. If a functionally equivalent amino acid sequence contains one or more amino acid substitutions relative to the reference sequence, these are typically conservative amino acid substitutions.
[0052] As used herein, a "conservative amino acid substitution" is a substitution in which one amino acid residue is replaced by another amino acid residue without eliminating the desired properties of the protein. Suitable conservative amino acid substitutions can be made by replacing one amino acid with another having similar hydrophobicity, polarity, and R chain length. See, for example, Watson et al., "Molecular Biology of the Gene," 4th edition, 1987, The Benjamin / Cummings Pub. Co., Menlo Park, CA, page 224. Examples of conservative amino acid substitutions include the following (note that certain categories are not mutually exclusive):
[0053] As used herein, the term "substantially identical" refers to the identity between a first amino acid sequence that contains a sufficient or minimum number of amino acid residues that are i) identical to the aligned amino acid residues in the second amino acid sequence or ii) conservatively substituted for the aligned amino acid residues in the second amino acid sequence, such that the first and second amino acid sequences have a common domain and / or a common functional activity and / or a common immunogenicity. For example, amino acid sequences containing a common domain or antigenic domain with at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are referred to as being sufficiently or substantially identical. In the context of nucleotide sequences, the term "substantially identical" is used herein to refer to a first nucleic acid sequence that contains a sufficient or minimum number of nucleotides that are identical to the aligned nucleotides in the second nucleic acid sequence, such that the first nucleotide sequence and the second nucleotide sequence encode a polypeptide having a common functional activity, or encode a common structural polypeptide domain or a common functional polypeptide activity, or encode a polypeptide having the same immunogenic properties.
[0054] As used herein, a chemical entity (e.g., a polypeptide) is "substantially pure" or "isolated" if it is the predominant chemical entity of its kind (e.g., a polypeptide) in a composition. This includes chemical entities that represent more than 50%, more than 80%, more than 90%, more than 95%, more than 98%, more than 99%, more than 99.5%, more than 99.9%, or more than 99.99% of the chemical entities of that kind in the composition. A substantially purified fraction is a composition in which the target substance accounts for at least about 50% (by mole) of all macromolecular substances present in the composition. Typically, a substantially pure composition means that about 80% to 90% or more of the macromolecular substances present in the composition are the purified substance of interest. If the composition consists essentially of a single macromolecular substance, the target substance is purified to essentially homogeneity (contaminating substances in the composition cannot be detected by conventional detection methods). For the purposes of this definition, solvent substances, small molecules, stabilizers (e.g., BSA), and elemental ionic substances are not considered macromolecular substances.
[0055] The phrase "isolated antibody" refers to an antibody produced in vivo or in vitro that has been removed from the source from which the antibody was produced (e.g., an animal, hybridoma, or other cell line such as recombinant insect, yeast, or bacterial cells that produce the antibody).
[0056] As used herein, the term "sequence identity" refers to the percentage of sequence identity between two polypeptide sequences or two nucleic acid sequences. In order to determine the percentage of identity of two amino acid sequences or two nucleic acid sequences, the sequences are compared for the purpose of optimal comparison (for example, a vacancy can be introduced in the sequence of the first amino acid or nucleic acid sequence to achieve the best comparison with the second amino acid or nucleic acid sequence). Then compare the amino acid residues or nucleotides at the corresponding amino acid positions or nucleotide positions. When the position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, the molecules are identical at this position. The percentage of identity between the two sequences is a function of the number of identical positions shared by the sequences (that is, the number of identical overlapping positions / total number of positions multiplied by 100%). In one embodiment, the two sequences have the same length. The determination of the percentage of identity between the two sequences can also be completed using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268, as modified in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877. This algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the NB LAST nucleotide program parameter set (e.g., for score = 100, word length = 12) to obtain nucleotide sequences homologous to the nucleic acid molecules of the present application. BLAST protein searches can be performed with the XBLAST program parameter set (e.g., score -50, word length = 3) to obtain amino acid sequences homologous to the protein molecules described herein. In order to obtain gapped alignments for comparison purposes, gapped BLAST can be used as described in Altschul et al., (1997) Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-BLAST can be used for iterative searches, which detects long-range relationships between molecules (supra). When using BLAST, gapped BLAST, and PSI-Blast programs, the default parameters of each program (e.g., XBLAST and NBLAST) can be used (see, e.g., the NCBI website). Another preferred non-limiting example of a mathematical algorithm for comparing sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0), which is part of the GCG sequence alignment software package.When utilizing the ALIGN program to compare amino acid sequences, the PAM120 weight residue table can be used, a gap length penalty of 12, and a gap penalty of 4. Techniques similar to those described above can be used to determine the percent identity between the two sequences with or without allowing gaps. When calculating percent identity, typically only exact matches are counted.
[0057] For antibodies, when the antibody sequences are maximally aligned by IMGT, the percent sequence identity can be determined. After alignment, if a subject antibody region (e.g., the entire mature variable region of a heavy or light chain) is compared to the same region of a reference antibody, the percent sequence identity between the subject antibody region and the reference antibody region is the number of positions occupied by identical amino acids in both the subject antibody region and the reference antibody region divided by the total number of aligned positions in the two regions, multiplied by 100 to convert to a percentage.
[0058] The amino acid sequence identity percentage can also be determined using the sequence comparison program NCBI-BLAST2 (Altschul et al., Nucleic Acids Res. 25: 3389-3402 (1997)). The NCBI-BLAST2 sequence comparison program can be obtained from the National Institutes of Health (Bethesda, Maryland). NCBI-BLAST2 uses several search parameters, all of which are set to default values, including, for example, unmasked = yes, chain = all, expected number of occurrences = 10, minimum low complexity length = 15 / 5, multi-pass e value = 0.01, multi-pass constant = 25, decay of final gapped alignment = 25, and scoring matrix = BLOSUM62.
[0059] In the case of amino acid sequence comparison using NCBI-BLAST2, the % amino acid sequence identity of a given amino acid sequence A to, with or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A having or comprising a certain % amino acid sequence identity to, with or against a given amino acid sequence B) is calculated as follows: 100 multiplied by a fraction X / Y, where X is the number of amino acid residues that are scored as identical matches by the sequence alignment program NCBI-BLAST2 in the alignment of A and B in that program, and where Y is the total number of amino acid residues in B. It will be understood that in the case where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not be equal to the % amino acid sequence identity of B to A. As used herein, the term "nucleic acid sequence" refers to a sequence of nucleoside or nucleotide monomers composed of naturally occurring bases, sugars, and intersugar (backbone) linkages and includes cDNA. The term also includes modified or substituted sequences comprising non-naturally occurring monomers or portions thereof. The nucleic acid sequence of the present application can be a deoxyribonucleic acid sequence (DNA) or a ribonucleic acid sequence (RNA), and can include naturally occurring bases, including adenine, guanine, cytosine, thymidine and uracil. The sequence can also contain modified bases. Examples of such modified bases include aza and deaza adenine, guanine, cytosine, thymidine and uracil; and xanthine and hypoxanthine. It should be understood that polynucleotides containing non-transcribable nucleotide bases can be used as probes in, for example, hybridization assays. Nucleic acids can be double-stranded or single-stranded, and represent sense strands or antisense strands. In addition, the term "nucleic acid" includes complementary nucleic acid sequences and optimized codons or synonymous codon equivalents.
[0060] As used herein, the term "isolated nucleic acid" refers to a nucleic acid that is substantially free of cellular material or culture medium when produced by recombinant DNA techniques or substantially free of chemical precursors or other chemicals when chemically synthesized. An isolated nucleic acid is also substantially free of the sequences that naturally flank the nucleic acid from which it is derived (i.e., the sequences located at the 5' and 3' ends of the nucleic acid).
[0061] All or part of the nucleic acid sequence molecule can be hybridized. The length of the hybridization portion is typically at least 15 (e.g., 20, 25, 30, 40 or 50) nucleotides. Those skilled in the art will recognize that the stability of the nucleic acid duplex or hybrid is determined by Tm, which is a function of sodium ion concentration and temperature in a sodium-containing buffer (Tm = 81.5°C-16.6 (Log10 [Na+]) + 0.41 (% (G+C)-600 / l), or similar equations). Therefore, the parameters in the washing conditions that determine hybridization stability are sodium ion concentration and temperature. In order to identify molecules that are similar but not identical to known nucleic acid molecules, it can be assumed that 1% mismatch results in a decrease in Tm of about 1°C. For example, if a nucleic acid molecule with> 95% identity is sought, the final washing temperature will be reduced by about 5°C. Based on these considerations, those skilled in the art will be able to easily select appropriate hybridization conditions. In a preferred embodiment, stringent hybridization conditions are selected. For example, stringent hybridization can be achieved using the following conditions: hybridization at 5x sodium chloride / sodium citrate (SSC) / 5x Denhardt solution / 1.0% SDS at Tm-5°C, based on the above equation, followed by washing with 0.2x SSC / 0.1% SDS at 60°C. Moderately stringent hybridization conditions include a washing step in 3x SSC at 42°C. However, it should be understood that equivalent stringency can be achieved using alternative buffers, salts, and temperatures. Additional guidance on hybridization conditions can be found in the following literature: Current Protocols in Molecular Biology, John Wiley & Sons, NY, 2002, and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001.
[0062] As used herein, the term "expression construct" refers to a polynucleotide comprising an expression control sequence operably linked to a heterologous nucleotide sequence (the heterologous nucleotide sequence, i.e., a sequence to which the expression control sequence is not usually linked in nature), which is the object of expression. As used herein, the term "expression vector" refers to a polynucleotide comprising an expression construct and a sequence sufficient to replicate in a host cell or insert into a host chromosome. Plasmids and viruses are examples of expression vectors. As used herein, the term "expression control sequence" refers to a nucleotide sequence that regulates the transcription and / or translation of a nucleotide sequence operably linked thereto. Expression control sequences include promoters, enhancers, repressors (transcriptional regulatory sequences), and ribosome binding sites (translation regulatory sequences).
[0063] As used herein, a nucleotide sequence is "operably linked" to an expression control sequence when the expression control sequence functions in a cell to regulate the transcription of the nucleotide sequence. This includes promoting transcription of the nucleotide sequence through interaction between a polymerase and a promoter.
[0064] As used herein, the term "vector" includes any intermediate vehicle for a nucleic acid molecule that enables, for example, the nucleic acid molecule to be introduced into a prokaryotic and / or eukaryotic cell and / or integrated into the genome, and includes plasmids, phagemids, phages, or viral vectors (e.g., retroviral-based vectors, lentiviral vectors, adeno-associated viral vectors, etc.). As used herein, the term "plasmid" generally refers to a construct of extrachromosomal genetic material (usually a circular DNA duplex) that can replicate independently of chromosomal DNA.
[0065] "Transfection" refers to the introduction of new genetic material into cells. It includes transformation (direct uptake and incorporation of exogenous genetic material from its surroundings through the cell membrane), transduction (introduction of foreign DNA into host cells by bacteriophage viruses) and conjugation.
[0066] As used herein, "host cell" refers to a recombinant cell that contains an expression construct.
[0067] As used herein, the term "biological sample" refers to a sample containing cells (eg, tumor cells) or biomolecules derived from cells.
[0068] As used herein, the terms "therapy", "treatment", "therapeutic intervention" and "improvement" refer to any activity that causes a decrease in the severity of symptoms. The terms "treatment" and "prevention" are not intended to be absolute terms. Treatment and prevention can refer to any delay in onset, improvement of symptoms, improvement in patient survival, increase in survival time or survival rate, etc. Treatment and prevention can be complete or partial. The therapeutic effect can be compared with an individual or individual set that has not received treatment, or with the same patient at different times before or during treatment. In some aspects, for example, compared with an individual before administration or a control individual that has not undergone treatment, the severity of the disease is reduced by at least 10%. In some aspects, the severity of the disease is reduced by at least 25%, 50%, 75%, 80% or 90%, or in some cases, it is no longer detectable using standard diagnostic techniques. "Treatment" and "treatment" can also mean to extend the survival period compared with the expected survival period when not receiving treatment. As used herein, "treatment" and "treatment" also include preventive treatment.
[0069] A composition or method that "comprising" or "includes" one or more listed elements may include other elements not specifically listed (e.g., an open-ended term intended to include, but not limited to). For example, a composition that "comprising" or "includes" an antibody may contain a single antibody or a combination of the antibody and other ingredients. In contrast, the phrase "consisting of" is closed, indicating that such embodiments do not include additional elements. The term "consisting essentially of" means including the listed elements and other elements that do not materially affect the basic and novel features of the claimed combination (e.g., partially closed terms). It should be understood that the aspects and embodiments described herein as "comprising" include "consisting of" and "consisting essentially of" embodiments.
[0070] As used herein, unless otherwise indicated, the following meanings apply. The word "may" is used in a permissible sense (i.e., meaning that it is possible) rather than a mandatory sense (i.e., meaning that it must). The singular forms "one / a kind (a)", "one / a kind (an)" and "the" include plural indicators. Therefore, for example, although other terms and phrases (such as "one or more") are used for one or more elements, the reference to "one / a kind of element" includes a combination of two or more elements. The phrase "at least one / a kind" includes "one / a kind", "one / a kind or more / multiple" and "multiple / multiple". Unless otherwise indicated, the term "or" is non-exclusive, i.e., covers both "and" and "or". The term "any" between a modifier and a sequence means each member of the modifier modification sequence. Therefore, for example, the phrase "at least 1, 2 or 3 any one" means "at least 1, at least 2 or at least 3". II. Chimeric Antigen Receptors
[0071] "Chimeric antigen receptor" or "CAR" is an engineered molecule comprising an optional signal peptide, a target binding domain, an optional hinge region, a transmembrane domain, an intracellular signaling domain, and an optional co-stimulatory domain. CAR is based on the structure of the T cell receptor, which is expressed on T cells and participates in cell-mediated immune responses. "Target binding domain" is also referred to herein as "antigen binding domain", and thus the term "target" encompasses "antigen".
[0072] The so-called "first generation" CAR has a targeting domain and a CD3ξ signal transduction domain. The so-called "second generation" CAR further includes a costimulatory domain (such as CD28 or 4-1BB domain). The so-called "third generation" CAR includes multiple costimulatory domains. The so-called "fourth generation" CAR (also referred to as "TRUCK") is engineered to release transgenic cytokines after CAR signaling.
[0073] A chimeric antigen receptor ("CAR") includes the following elements: (1) an optional signal peptide, (2) a target binding domain, (3) an optional hinge region; (4) a transmembrane region; (5) an intracellular domain comprising a signal transduction domain. Optionally, CAR may include any one of the following: a CD3ζ signal transduction domain, an Fc receptor signal transduction domain, a co-stimulatory (signal transduction) domain. That is, these optional elements may be included in addition to or in place of other optional elements. The target binding domain is heterologous to at least one of the other domains. That is, the target binding domain does not naturally occur on a T cell receptor, or is not in the same protein as at least one of the other domains.
[0074] The "target binding domain" provides binding specificity to the CAR. The "signal peptide" guides the polypeptide through the cell membrane. For the so-called "universal CAR", the target binding domain can be combined with the domain of the antibody that binds the target antigen. The "hinge region" is a flexible connector region, such as a natural or synthetic polypeptide, or any other type of molecule, thereby providing structural flexibility and spacing with the flanking polypeptide region. The "transmembrane domain" is a transmembrane protein domain, which is usually hydrophobic. After binding, the "signal transduction domain" or "signaling domain" transmits the signal to the cell through the signal transduction pathway. This signal transduction activates the activity of the cell. The "costimulatory domain" is an auxiliary signaling domain that further transmits the signal.
[0075] In some embodiments, the CAR comprises: (i) a target binding domain (also referred to herein as an antigen binding domain) reactive with a citrullinated protein or a citrullinated fragment thereof, such as VH-VL or VL-VH, wherein the two variable domains are separated by a flexible linker of 15-25 amino acids in length; (ii) hinge domain; (iii) a co-stimulatory domain; and (iv) intracellular signaling domain (also referred to herein as activation domain). That is, in some embodiments, CAR comprises an antigen binding domain fused to a CAR platform, the platform comprising a hinge domain, a transmembrane domain, and an intracellular domain comprising a co-stimulatory domain and an activation domain. CAR may further include a signal peptide (also referred to herein as a leader sequence) to direct the expression of CAR to the surface of cells (such as Treg).
[0076] In some embodiments, the CAR comprises an antigen binding domain fused in frame to a CAR platform comprising an amino acid sequence of SEQ ID NO: 15, SEQ ID: 17, SEQ ID NO: 28, and SEQ ID: 19. In other embodiments, the CAR comprises an antigen binding domain fused in frame to a CAR platform comprising an amino acid sequence of SEQ ID NO: 30, SEQ ID: 16, SEQ ID NO: 28, and SEQ ID: 19. In some embodiments, the CAR comprises an antigen binding domain fused in frame to a CAR platform comprising an amino acid sequence of SEQ ID NO: 30, SEQ ID: 16, SEQ ID NO: 29, and SEQ ID: 19. In other embodiments, the CAR comprises an antigen binding domain fused in frame to a CAR platform comprising an amino acid sequence of SEQ ID NO: 30, SEQ ID: 16, SEQ ID NO: 29, and SEQ ID: 19. A. Signal peptide
[0077] The signal peptide may be any peptide having the function of allowing the polypeptide to pass through the cell membrane. The signal peptide may be derived from CD4, CD8, CD28, TLR or immunoglobulin receptor family.
[0078] For example, a signal peptide may comprise the following sequence: MLLLVTSLLLCELPHPAFLLIP(SEQ ID NO:18); or MALPVTALLLPLALLLHAAR (SEQ ID NO: 23). B. Target Binding Domain 1. Structure
[0079] The target binding domain may include any polypeptide containing a target binding function, such as an antibody as defined herein. In one embodiment, the target binding domain may include an antibody form retaining antigen binding activity as defined herein. In one embodiment, the target binding domain may include a single-chain antibody (scFV). ScFv can be connected to a transmembrane domain via a hinge domain, and the length, flexibility and source of the hinge domain provide variability for the design of CAR, and can promote interaction with antigens together with the transmembrane domain, promote the construction of immune synapses, and affect the association of CAR with other proteins required for conferring a stable activation signal. 2. Target / Antigen
[0080] The chimeric antigen receptor disclosed herein comprises a target binding domain (also referred to herein as an antigen binding domain) that binds to a citrullinated antigen (e.g., those found in the synovium of a subject with rheumatoid arthritis). In particular, the target binding domain may bind to one or more of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, (iii) citrullinated fibrinogen, and (iv) citrullinated peptides thereof. In some embodiments, the target binding domain may bind to a citrullinated peptide fragment of (i)-(iii), wherein the peptide fragment is at least 10 amino acids in length, such as at least 12 amino acids, at least 14 amino acids, or at least 16 amino acids in length. In some embodiments, the target binding domain further binds to tenascin C. In some embodiments, the target binding domain may bind to two or more of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, (iii) citrullinated fibrinogen, and (iv) tenascin C, or citrullinated peptide fragments thereof.
[0081] In some embodiments, the target domain is one or more citrullinated peptides selected from the following sequences: ST(Cit)SVSSSSY(Cit)(Cit)MFGG(SEQ ID NO:24); VYAT(Cit)SSAV(Cit)L(Cit)SSV(SEQ ID NO:25); (Cit)PAPPPISGGGY(Cit)A(Cit)(SEQ ID NO:26); SHQEST(Cit)GRSRGRSGRSGS (SEQ ID NO: 27).
[0082] In some embodiments, the antigen binding domain binds to one or more citrullinated peptides, but does not bind to the non-citrullinated counterpart. In some embodiments, the antigen binding domain binds to the citrullinated vimentin peptide as shown in SEQ ID NO:24, but does not bind to STRSVSSSSYRRMFGG (SEQ ID NO:45). In some embodiments, the antigen binding domain binds to the citrullinated vimentin peptide as shown in SEQ ID NO:25, but does not bind to VYATRSSAVRLRSSV (SEQ ID NO:46). In some embodiments, the antigen binding domain binds to the citrullinated fibrinogen peptide as shown in SEQ ID NO:26, but does not bind to RPAPPPISGGGYRAR (SEQ ID NO:47). In some embodiments, the antigen binding domain binds to the citrullinated filaggrin peptide as shown in SEQ ID NO:27, but does not bind to SHQESTRGRSRGRSGRSGS (SEQ ID NO:48).
[0083] The target binding domain may comprise sequences from the VH and VL domains of an antibody. In some embodiments, the target binding domain may comprise sequences from a heavy chain-only antibody or antibody fragment having only two VH domains. This includes specific CDR sets from VH and VL domains. In some embodiments, the target binding domain comprises CDRs from the VH domain of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, the target binding domain comprises CDRs from the VL domain of SEQ ID NO: 3 or SEQ ID NO: 4. In some embodiments, the target binding domain comprises CDRs from the VH and VL domains of SEQ ID NO: 1 or SEQ ID NO: 3, respectively. In some embodiments, the target binding domain comprises CDRs from the VH and VL domains of SEQ ID NO: 1 or SEQ ID NO: 4, respectively. In some embodiments, the target binding domain comprises CDRs from the VH and VL domains of SEQ ID NO: 1 or SEQ ID NO: 4, respectively. In some embodiments, the target binding domain comprises CDRs from the VH and VL domains of SEQ ID NO: 2 or SEQ ID NO: 3, respectively. In some embodiments, the target binding domain comprises CDRs from the VH and VL domains of SEQ ID NO: 2 or SEQ ID NO: 4, respectively.
[0084] In some embodiments, the target binding domain comprises complementarity determining regions (CDRs) from the VH and VL domains of SEQ ID NO: 1 (SBT01 VH (M)) and SEQ ID NO: 4 (SBT01 VL (G)). In some embodiments, the VH domain of the target binding domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO: 32, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 36, and the VL domain of the target binding domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO: 39, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO: 43. area SEQ ID Sequence fragment Residue length LFR1 NO:38 SYVLTQPPSVSVAPGKTARITC 1-22 22 CDR-L1 NO:39 GGNNIGSKSVH 23-33 11 LFR2 NO:40 WYQQKPGQAPVLVIY 34-48 15 CDR-L2 NO:41 YDSDRP 49-55 7 LFR3 NO:42 GIPERFSGSNSGNTATLTISRVEAGDEADYYC 56-87 32 CDR-L3 NO:43 QVWDSSSDHQV 88-98 11 LFR4 NO:44 FGTGTKVTV 99-108 11
[0085] In certain embodiments, the target binding domain comprises a VH sequence selected from the group consisting of: (1)SBT01 VH(M) (2) SBT01 VH(G) or A sequence having at least any of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequences, provided that the target binding domain binds to a citrullinated antigen as described herein.
[0086] The target binding region may comprise a VL sequence selected from the group consisting of: (1)SBT01 VL(M) (2)SBT01 VL(G) or A sequence having at least any of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequences, provided that the target binding domain binds to a citrullinated antigen as described herein.
[0087] In another embodiment, the antigen binding region comprises a scFV comprising one or more VH domains comprising the amino acid sequence of the VH domain of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, the antigen binding region comprises a scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 1 or SEQ ID NO: 2, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0088] In some embodiments, the scFV comprises a VL domain of SEQ ID NO: 3 or SEQ ID NO: 4. In some embodiments, the antigen binding region comprises a scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% of any one of SEQ ID NO: 3 or SEQ ID NO: 4, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0089] In some embodiments, the scFV domain comprises the VH and VL domains of SEQ ID NO: 1 and SEQ ID NO: 3, respectively. In some embodiments, the antigen binding region comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 1 or SEQ ID NO: 3, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, a linker selected from SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 22 is placed between the VH and VL domains.
[0090] In some embodiments, the scFV domain comprises the VH and VL domains of SEQ ID NO: 1 and SEQ ID NO: 4, respectively. In some embodiments, the antigen binding region comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 1 and SEQ ID NO: 4, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, a linker selected from SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 22 is placed between the VH and VL domains.
[0091] In some embodiments, the scFV domain comprises the VH and VL domains of SEQ ID NO: 2 and SEQ ID NO: 3, respectively. In some embodiments, the antigen binding region comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 2 and SEQ ID NO: 3, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, a linker selected from SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 22 is placed between the VH and VL domains.
[0092] In some embodiments, the scFV domain comprises the VH and VL domains of SEQ ID NO: 2 and SEQ ID NO: 4, respectively. In some embodiments, the antigen binding region comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 2 and SEQ ID NO: 4, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, a linker selected from SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO: 22 is placed between the VH and VL domains.
[0093] In another embodiment, the antigen binding region comprises a scFV comprising an amino acid sequence selected from the group consisting of: SBT01G-VHVL-GGGSx3 connector-pSB_0149 (GGGSx3 connector is underlined); SBT01G-VHVL-Whitlow 218 connector-pSB_0158 (Whitlow 218 connector underlined); SBT01G-VHVL-AB pur connector-pSB_0159 (AB pur connector underlined); or A sequence having at least any of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequences, provided that the target binding domain binds to a citrullinated antigen as described herein.
[0094] For example, the linker may comprise the following sequence: GGGGSGGGGSGGGGS (SEQ ID NO: 20) GGGSx3 linker; or GSTSGSGKPGSGEGSTKG (SEQ ID NO: 21) Whitlow 218 linker; or ASSGGSTSGSGKPGSGEGSSGSAR (SEQ ID NO: 22) AB pur linker.
[0095] Optionally, any of the foregoing sequences may include sets of CDRs from the above-described VH and VL domains. C. Hinge region
[0096] In some embodiments, the hinge region of the disclosed CAR can be selected from the extracellular domains of CD8, CD4 or CD28, the Fc region of an IgG1 antibody, or the extracellular domain of any TLR receptor as known to those skilled in the art and can be found in the GenBank database.
[0097] For example, the hinge region may comprise the following sequence: IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP(SEQ ID NO:30)(CD28); or TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTC GVLLLSLVITLYC (SEQ ID NO: 15) (CD8); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned hinge region sequence. D. Transmembrane domain
[0098] The transmembrane domain may include a transmembrane domain of an immunoglobulin family receptor (such as CD8). The intracellular domain may be selected from any transmembrane molecule on a T cell. For example, the transmembrane (TM) domain of the disclosed CAR may include a TM domain of CD2, CD3, CD16, CD32, CD64, CD28, CD247, 4-1BBL, CD4 or CD8.
[0099] For example, a transmembrane domain may comprise the following sequence: FWVLVVVGGVLACYSLLVTVAFIIFWV(SEQ ID NO:16); or IYIWAPLAGTCGVLLLSLVITLYC(SEQ ID NO:17); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned hinge region sequence. E. Signal transduction domain 1.CD3ζ signal transduction domain
[0100] In some embodiments, the signal transduction domain includes a CD3 zeta signaling domain. The CD3 zeta signaling domain of the disclosed CAR molecule can include a CD3 zeta amino acid sequence, such as a signal transduction domain of CD3 zeta.
[0101] For example, a CD3ζ signaling domain may comprise the following sequence: or The sequence of the CD3ζ signal transduction domain has 80%, 85%, 90%, 95%, 97%, 98%, 99% or Sequences with at least any one of 99.5% sequence identity.
[0102] For example, the CD3ζ signaling domain can include amino acids 21-163, 31-142, 68-89 and / or 138-158 of the sequence shown in SEQ ID NO: 19, or a functional variant thereof (e.g., having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 10-20 amino acid substitutions, deletions or additions). 2. Fc receptor signal transduction domain
[0103] In some embodiments, the signal transduction domain includes an Fc signaling domain. The Fc signaling domain can be any of the Fc-α, Fc-γ, Fc-ε, Fc-μ and Fc-δ receptors. For example, the Fc receptor signaling domain may include amino acids (e.g., one or more ITAM domains) that participate in the interaction with Src (e.g., Fgr, Fyn, Hck, Lyn, Yes and Src) and ZAP-70 family kinases (see, e.g., Sanchez-Mejorada et al. (1998) J. Leukocyte Biol. 63:531; Garcia-Garcia et al. (2002) J. Leukocyte Biol. 72:1092). In some embodiments, the Fc receptor signaling domain includes at least one ITAM domain, e.g., at least one ITAM domain from any of the Fc-α, Fc-γ, Fc-ε, Fc-μ and Fc-δ receptors, or is substantially identical thereto.
[0104] The sequence can also be found as follows: F. Co-stimulatory domain
[0105] In addition to the signal transduction domains of CD3ζ or Fc receptors, the CAR of the present disclosure may also include one or more costimulatory domains.Costimulatory domains may be derived from, for example, CD28, 4-1BB, CD2, CD27, CD30, OX40, CD40, PD-1, PD-L1, PD-L2, ICOS, LFA-1, CD7, LIGHT, NKG2C, B7-H3, CD83L, B7-1 (CD80), B7-2 (CD86), B7-H3, B7-H4, etc. CAR constructs may contain two or more costimulatory signaling domains (e.g., CD28 and 4-1BB).
[0106] One or more co-stimulatory domains may be located between the signal transduction domain and the transmembrane region.
[0107] In certain embodiments, the CD28 costimulatory domain may comprise the following sequence: RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS(SEQ ID NO:29); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0108] In certain embodiments, the 41BB costimulatory domain may comprise the following sequence: KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQ ID NO:28); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence. III. Nucleic Acids A. Nucleic acid encoding CAR
[0109] Disclosed herein are nucleic acid molecules (polynucleotides) comprising nucleotide sequences encoding the CAR of the present disclosure. The nucleic acid of the disclosed CAR can be in the form of DNA or RNA. DNA includes cDNA, genomic DNA, and synthetic DNA; and can be double-stranded or single-stranded, and if single-stranded, can be a coding strand or a non-coding (antisense) strand. RNA includes mRNA, siRNA, sRNA, ssRNA, etc.
[0110] For example, the nucleic acid may comprise a nucleotide sequence encoding a polypeptide of any one of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4. In certain embodiments, the nucleotide sequence encoding the VH domain comprises: (1)SBT01 VH(M) (2) SBT01 VH(G) or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0111] In certain embodiments, the nucleotide sequence encoding the VL domain comprises: (1)SBT01 VL(M) (2)SBT01 VL(G) or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0112] In another embodiment, the nucleic acid molecule encoding the VH domain comprises SEQ ID NO: 8 or SEQ ID NO: 9. In some embodiments, the nucleic acid molecule encoding the VH domain comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 8 or SEQ ID NO: 9, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0113] In some embodiments, the nucleic acid molecule encoding the VL domain comprises SEQ ID NO: 10 or SEQ ID NO: 11. In some embodiments, the nucleic acid molecule encoding the VL domain comprises a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% of any one of SEQ ID NO: 10 or SEQ ID NO: 11, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0114] In some embodiments, the nucleic acid molecule encoding the scFV domain comprises SEQ ID NO: 8 and SEQ ID NO: 10. In some embodiments, the nucleic acid molecule encoding the scFV comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 8 or SEQ ID NO: 10, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0115] In some embodiments, the nucleic acid molecule encoding the scFV domain comprises SEQ ID NO: 8 and SEQ ID NO: 11. In some embodiments, the nucleic acid molecule encoding the scFV comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 8 or SEQ ID NO: 11, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0116] In some embodiments, the nucleic acid molecule encoding the scFV domain comprises SEQ ID NO: 9 and SEQ ID NO: 10. In some embodiments, the nucleic acid molecule encoding the scFV comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 9 or SEQ ID NO: 10, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0117] In some embodiments, the nucleic acid molecule encoding the scFV domain comprises SEQ ID NO: 9 and SEQ ID NO: 11. In some embodiments, the nucleic acid molecule encoding the scFV comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of any one of SEQ ID NO: 9 or SEQ ID NO: 11, provided that the scFV domain binds to a citrullinated antigen as described herein.
[0118] In another embodiment, the nucleic acid molecule encodes a scFv molecule and has the following nucleotide sequence: SBT01G-VHVL-GGGSx3 connector-pSB_0149 (GGGSx3 connector is underlined); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0119] In another embodiment, the nucleic acid molecule encodes a scFv molecule and has the following nucleotide sequence: SBT01G-VHVL-Whitlow 218 connector-pSB_0158 (Whitlow 218 connector underlined); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0120] In another embodiment, the nucleic acid molecule encodes a scFv molecule and has the following nucleotide sequence: SBT01G-VHVL-AB pur connector-pSB_0159 (AB pur connector underlined); or A sequence having at least any one of 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% sequence identity to the aforementioned sequence.
[0121] Optionally, these may include sequences encoding the sets of CDRs from the VH and VL domains described herein.
[0122] Polynucleotide variants may contain changes in coding regions, non-coding regions, or both. In some embodiments, polynucleotide variants contain changes that produce silent substitutions, additions or deletions but do not change the properties or activity of the encoded CAR polypeptides. In some embodiments, polynucleotide variants contain changes that do not produce any changes in the amino acid sequence. In some embodiments, due to the degeneracy of the genetic code, polynucleotide variants contain "silent" substitutions. Polynucleotide variants can be generated for a variety of reasons, for example, to optimize codon expression for a specific host.
[0123] In some embodiments, the polynucleotides described herein are isolated.
[0124] The polynucleotide encoding CAR is an isolated molecule, or can be included in a vector (e.g., a plasmid, a cosmid, an artificial chromosome or a virus). Such vectors can be used to transfect target cells. B. Expression Constructs and Vectors
[0125] The polynucleotides encoding the CAR of the present disclosure may include a regulatory element operably connected to the nucleotide sequence encoding CAR. For example, the polynucleotides may include one or more transcriptional regulatory elements (such as promoters or enhancers), and when the polynucleotides are present in cells, the one or more transcriptional regulatory elements cause the sequence encoding CAR to be expressed in the cell.
[0126] Nucleic acids disclosed herein can be incorporated into vectors capable of transfecting cells. Such vectors include, but are not limited to, viral vectors, plasmids, and microvesicles, such as liposomes. Exemplary viral vectors are adenovirus vectors Ad, AAV, slow viruses, and vesicular stomatitis virus (VSV) and retroviruses. Slow viruses are a genus of the Retroviridae family, and include HIV, SIV, and FIV. Slow viruses can deliver large amounts of genetic material to the DNA of host cells. They can infect non-dividing cells. IV. Cells
[0127] In some embodiments, the recombinant (host) cell has a nucleic acid molecule encoding the disclosed CAR, wherein the nucleic acid molecule may further include an expression control sequence operably connected to the nucleotide sequence encoding the CAR. The assembled CAR (by synthesis, site-directed mutagenesis or another method known to those skilled in the art), the nucleic acid molecule encoding the disclosed CAR can be inserted into an expression vector and operably connected to the expression control sequence suitable for expressing the disclosed CAR in the desired host. The correct assembly can be confirmed by nucleotide sequencing, restriction endonuclease mapping and / or expression of CAR polypeptides in a suitable host. As is well known in the art, in order to obtain a high expression level of the transfected gene in the host, the gene must be operably connected to the transcription and translation expression control sequences that work in the selected expression host.
[0128] The present disclosure also provides cells (e.g., recombinant cells) comprising nucleic acid molecules encoding CAR and / or expressing CAR.
[0129] The nucleic acid molecules encoding the disclosed CAR can be delivered to host cells by plasmids or viral vectors as known to those skilled in the art, including but not limited to T cells, B cells, myeloid progenitor cells, macrophages, etc. The resulting recombinant (host) cells may include but are not limited to T cells, CD4 T cells, Treg cells, CD8αT cells, CD8βT cells, T helper cells, granulocytes (neutrophils, basophils, eosinophils), megakaryocytes, monocytes, macrophages and dendritic cells, T memory stem cells, and cells expressing class I or class II MHC. In some embodiments, the recombinant (host) cells with nucleic acid molecules encoding the disclosed CAR can be selected from the following myeloid progenitor cells as known to those skilled in the art: myeloid common progenitor cells, granulocyte macrophage progenitor cells, megakaryocyte erythrocyte progenitor cells, granulocyte progenitor cells and monocyte progenitor cells. In some embodiments, myeloid cells are autologous or allogeneic cells.
[0130] In some embodiments, the cells expressing the CARs of the present disclosure are Treg cells. reg T cells are specialized T cell subsets whose function is to suppress immune responses and thus maintain homeostasis and self-tolerance. reg It can inhibit T cell proliferation and cytokine production and plays a key role in preventing autoimmunity. reg is characterized by the expression of FoxP3. regSurface markers include CD4, CD25 high (high molecular density) and CD127 low (low molecular density). Mouse and human Treg express GITR / AITR and CTLA-4. Human CD4+FoxP3+Treg cells can be divided into three subsets: (1) CD45RA+CD25+FoxP3l0w resting Treg cells, (2) CD45RO+CD25highFoxP3high activated Treg cells, and (3) CD45RO+CD25+FoxP3low non-suppressive effector T cells (Teff) that produce pro-inflammatory cytokines.
[0131] The cells to be transformed with the nucleic acids disclosed herein can be cells taken from the subject to which the recombinant cells are to be administered. In this way, the problem of allogeneic immune responses can be alleviated.
[0132] The cells can be expanded ex vivo prior to administration to a subject.
[0133] Treg cells that have incorporated nucleic acids expressing the CARs of the present disclosure can express these CARs and be used in the methods described herein to treat rheumatoid arthritis.
[0134] In addition, the protein produced by the transformed / recombinant host can be purified according to any suitable method. Such methods include chromatography (e.g., ion exchange, affinity and grading (sizing) column chromatography), centrifugation, differential solubility or any other standard techniques for protein purification. Affinity tags (such as hexa-histidine, maltose binding domain, influenza capsid sequence and glutathione-S-transferase) can be attached to the protein to allow easy purification by appropriate affinity columns. In some embodiments, the protein can also be physically characterized using techniques such as proteolysis, high performance liquid chromatography (HPLC), nuclear magnetic resonance and x-ray crystallography. V. Composition
[0135] Also disclosed are pharmaceutical compositions comprising recombinant cells having nucleic acid molecules encoding the disclosed CAR polypeptides and / or expressing the disclosed CAR polypeptides and a pharmaceutically acceptable carrier; and methods for treating rheumatoid arthritis.
[0136] As used herein, the term "pharmaceutical composition" refers to a composition comprising a pharmaceutical compound (eg, a drug or recombinant Treg cells as described herein) and a pharmaceutically acceptable carrier.
[0137] As used herein, the term "pharmaceutically acceptable" refers to a carrier that is compatible with the other ingredients of a pharmaceutical composition and can be safely administered to a subject. The term is used synonymously with "physiologically acceptable" and "pharmacologically acceptable". According to the present disclosure, pharmaceutical compositions and their preparation and use techniques are known to those skilled in the art. For a detailed list of suitable pharmacological compositions and their administration techniques, reference may be made to articles such as Remington's Pharmaceutical Sciences, 17th ed. 1985; Brunton et al., "Goodman and Gilman's The Pharmacological Basis of Therapeutics," McGraw-Hill, 2005; University of the Sciences in Philadelphia (ed.), "Remington: The Science and Practice of Pharmacy," Lippincott Williams & Wilkins, 2005; and University of the Sciences in Philadelphia (ed.), "Remington: The Principles of Pharmacy Practice," Lippincott Williams & Wilkins, 2008.
[0138] Pharmaceutically acceptable carriers are usually sterile, at least for human use. Pharmaceutical compositions usually contain agents for buffering and preservation, and may include buffers and carriers for appropriate delivery, depending on the route of administration. Examples of pharmaceutically acceptable carriers include, but are not limited to, physiological (0.9%) saline, phosphate buffered saline (PBS), Hank's balanced salt solution (HBSS), and various electrolyte solutions (such as PlasmaLyte ATM (Baxter)).
[0139] The pharmaceutical compositions can be formulated for any route of administration, including mucosal (eg, nasal, sublingual, vaginal, buccal, or rectal), parenteral (eg, subcutaneous, intravenous, intramuscular, or intraarterial injection (bolus or infusion)), oral, or transdermal.
[0140] Injectable (e.g., intravenous) compositions can include a solution of a composition suspended in an acceptable carrier (e.g., an aqueous carrier). Any of a variety of aqueous carriers can be used, such as water, buffered water, 0.4% saline, 0.9% isotonic saline, 0.3% glycine, 5% dextrose, etc., and glycoproteins such as albumin, lipoprotein, globulin, etc., for enhancing stability can be included. Typically, physiological buffered saline (135-150mM NaCl) is used. The composition can contain pharmaceutically acceptable auxiliary substances close to physiological conditions, such as pH regulators and buffers, tension regulators, wetting agents, such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc. In some embodiments, the composition can be formulated in a kit for intravenous administration.
[0141] Formulations suitable for parenteral administration (e.g., by intraarticular (in a joint), intravenous, intramuscular, intratumoral, intradermal, intraperitoneal, and subcutaneous routes) include aqueous and nonaqueous isotonic sterile injection solutions, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient; and aqueous and nonaqueous sterile suspensions, which may include suspending agents, solubilizers, thickeners, stabilizers, and preservatives. Injection solutions and suspensions may also be prepared from sterile powders, granules, and tablets. In the practice of the present invention, the composition may be administered, for example, by intravenous infusion, topical, intraperitoneal, intravesical, or intrathecal administration. The formulation of the composition may be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials.
[0142] The cells may be cryopreserved. Cryopreservation may include formulating the cells with a cryopreservative such as DMSO. Commercially available culture media include, for example, those available from Millipore Sigma. and
[0143] The composition can be formulated into a dosage form for administration. The term "dosage form" refers to a specific form of the drug and depends on the route of administration. Examples of dosage forms include, but are not limited to, dispersions; suppositories; ointments; cataplasms (caulding); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols (e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal administration to patients, including suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions or water-in-oil liquid emulsions), solutions and elixirs; liquid dosage forms suitable for parenteral administration to patients; and sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to provide liquid dosage forms suitable for parenteral administration to patients.
[0144] The terms "dose" and "dosage" are used interchangeably herein. Dose refers to the amount of active ingredient given to an individual at each administration. The dose will vary according to many factors, including the frequency of administration; the size and tolerance of the individual; the severity of the condition; the risk of side effects; the route of administration; and the imaging modality of the detectable marker (if present). Those skilled in the art will recognize that the dose may be modified according to the above factors or based on the progress of the treatment.
[0145] The pharmaceutical preparation can be packaged or prepared in unit dosage form. In this form, the preparation is subdivided into unit doses containing appropriate amounts of active ingredients, for example, according to the dosage of the therapeutic agent or the concentration of the composition. The unit dosage form can be a packaged preparation containing discrete amounts of the preparation. If desired, the composition can also contain other compatible therapeutic agents.
[0146] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a complementarity determining region (CDR) from a VH domain of SEQ ID NO: 1 or SEQ ID NO: 2. In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a CDR from a VL domain of SEQ ID NO: 3 or SEQ ID NO: 4. In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising CDRs from VH and VL domains of SEQ ID NO: 1 and SEQ ID NO: 3. In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising CDRs from VH and VL domains of SEQ ID NO: 1 and SEQ ID NO: 4. In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising CDRs from VH and VL domains of SEQ ID NO: 2 and SEQ ID NO: 3. In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising CDRs from SEQ ID NO:2 and SEQ ID NO:4 VH and VL domains. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0147] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising CDRs from the VH and VL domains of SEQ ID NO: 1 (SBT01 VH (M)) and SEQ ID NO: 4 (SBT01 VL (G)). In some embodiments, the VH domain of the CAR polypeptide comprises a VH-CDR1 comprising an amino acid sequence of SEQ ID NO: 32, a VH-CDR2 comprising an amino acid sequence of SEQ ID NO: 34, and a VH-CDR3 comprising an amino acid sequence of SEQ ID NO: 36, and the VL domain of the CAR polypeptide comprises a VL-CDR1 comprising an amino acid sequence of SEQ ID NO: 39, a VL-CDR2 comprising an amino acid sequence of SEQ ID NO: 41, and a VL-CDR3 comprising an amino acid sequence of SEQ ID NO: 43. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8α T cell, a CD8β T cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage, and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0148] In another embodiment, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide comprising scFV, the scFV comprising one or more VH domains containing the amino acid sequence of the VH domain of SEQ ID NO:1 or SEQ ID NO:2. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises an scFV, which comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO:1 or SEQ ID NO:2, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0149] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a scFV containing a VL domain of SEQ ID NO:3 or SEQ ID NO:4. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO:3 or SEQ ID NO:4, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0150] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a scFV containing SEQ ID NO:1 and SEQ ID NO:3 VH and VL domains. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises a scFV, which comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO:1 or SEQ ID NO:3, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0151] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a scFV containing SEQ ID NO: 1 and SEQ ID NO: 4 VH and VL domains. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises an scFV comprising an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO: 1 and SEQ ID NO: 4, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0152] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a scFV containing SEQ ID NO:2 and SEQ ID NO:3 VH and VL domains. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises a scFV, which comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO:2 and SEQ ID NO:3, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell.
[0153] In some embodiments, the composition of the present invention comprises a recombinant cell having a nucleic acid molecule encoding a CAR polypeptide, the CAR polypeptide comprising a scFV containing SEQ ID NO:2 and SEQ ID NO:4 VH and VL domains. In some embodiments, the nucleic acid molecule encoding the CAR polypeptide comprises a scFV, which comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, 98%, 99% or 99.5% of SEQ ID NO:2 and SEQ ID NO:4, provided that the scFV domain binds to a citrullinated antigen as described herein. In some embodiments, the cell is a T cell, a CD4 T cell, a Treg cell, a CD8αT cell, a CD8βT cell, a T helper cell, a granulocyte (neutrophil, basophil, eosinophil), a megakaryocyte, a monocyte, a macrophage and a dendritic cell or a T memory stem cell. In some embodiments, the cell is a Treg cell. VI. How to use
[0154] T cells expressing the CAR disclosed herein, and in particular Treg cells, can be used to treat rheumatoid arthritis. The method of use includes administering an effective amount of a pharmaceutical composition of the present disclosure to a subject in need thereof (e.g., a subject suffering from rheumatoid arthritis).
[0155] As used herein, the term "subject" refers to an individual animal. As used herein, the term "patient" refers to a subject under the care or supervision of a healthcare provider (such as a doctor or nurse). Subjects include mammals, such as humans and non-human primates (such as monkeys), as well as dogs, cats, horses, cows, rabbits, rats, mice, goats, pigs and other mammalian species. Subjects may also include birds. Patients may be individuals seeking treatment, monitoring, adjustment or modification of existing treatment regimens, etc. The term "rheumatoid arthritis subject" refers to an individual who has been diagnosed with rheumatoid arthritis. Rheumatoid arthritis patients may include individuals who have not yet received treatment, are currently receiving treatment, have received treatment, and those individuals who have stopped treatment.
[0156] As used herein, the terms "effective amount", "effective dose" and "therapeutically effective amount" refer to the amount of a medicament sufficient to produce a desired response (such as reducing or eliminating the signs or symptoms of a condition or improving a disorder). In some examples, an "effective amount" is an amount that treats (including preventing) one or more symptoms and / or underlying causes of any disorder or disease and / or prevents disease progression. For example, for a given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90% or at least 100% in the therapeutic effect. The therapeutic efficacy can also be expressed as a "fold" increase or decrease. For example, compared to a control, a therapeutically effective amount can have an effect of at least 1.2 times, 1.5 times, 2 times, 5 times or more.
[0157] The pharmaceutical composition can be administered by any suitable route, including but not limited to intravenous, subcutaneous, intramuscular or intraperitoneal routes. The example of the administration of the pharmaceutical composition includes storing the composition in a sterile isotonic aqueous saline solution for injection at 10mg / ml at 4°C, and diluting it in 100ml or 200ml of 0.9% sodium chloride for injection before being applied to the patient. The pharmaceutical composition is administered by intravenous infusion over a 1-hour course with a dosage between 0.2 and 10mg / kg. In other embodiments, the pharmaceutical composition is administered by intravenous infusion over a time period between 15 minutes and 2 hours. In yet other embodiments, the administration procedure is via subcutaneous push injection.
[0158] The dosage of composition is selected to provide effective therapy for the patient, and is less than 0.1mg / kg body weight to about 25mg / kg body weight or in the range of 1mg-2g / patient. In some cases, dosage is in the range of 1-100mg / kg or about 50mg-8000mg / patient. The dosage can be repeated with appropriate frequency, and the frequency can be in the range of once daily to once every three months, depending on the pharmacokinetics (e.g., the half-life of the composition in circulation) and pharmacodynamic response (e.g., the duration of the therapeutic effect of the composition) of the composition. In some embodiments, the half-life in vivo between about 7 and about 25 days and the composition administration are repeated between once a week and once every 3 months.
[0159] Administration can be periodic. Depending on the route of administration, the dosage can be administered, for example, once every 1, 3, 5, 7, 10, 14, 21 or 28 days or longer (e.g., once every 2, 3, 4 or 6 months). In some cases, administration is more frequent, for example, 2 or 3 times a day. As will be appreciated by those skilled in the art, the patient can be monitored to adjust the dosage and frequency of administration according to treatment progress and any adverse side effects.
[0160] Thus, in some embodiments, additional administrations are dependent on the patient's progress, e.g., the patient is monitored between administrations. For example, after the first administration or round of administration, the patient's tumor growth rate, recurrence (e.g., in the case of a postoperative patient), or general disease-related symptoms (e.g., weakness, pain, nausea, etc.) can be monitored.
[0161] In certain embodiments, the T cells described herein are administered to the synovium of a joint of a subject with rheumatoid arthritis. Such administration can be by direct injection into the joint.
[0162] An exemplary method of the present disclosure includes separating T lymphocytes from a biological sample obtained from a subject. Such T cells can be separated by immunoaffinity (e.g., using a derived solid support and anti-CD4 antibodies). CD4+ regulatory T cells (Treg) can be separated from non-Treg cells based on their marker characteristics. Treg cells are CD4+, CD25+, CD127lo. Non-Treg cells are: CD4+, CD25+ and CD127+. The separated Treg cells are then transfected with an expression vector encoding a chimeric antigen receptor (CAR) of the present disclosure. Amplify the transfected cells. The amplified cells are administered to a subject. VII. Kit
[0163] As used herein, the term "kit" refers to a collection of items intended to be used together. The kit may optionally include a reference agent and / or instructions for use thereof. The kit may further include a transport container suitable for containing a container (such as a vial) containing a composition as disclosed herein. The kit may include a container containing a collection of items.
[0164] The kit of the present disclosure may include a pharmaceutical composition as described herein, contained in a container (e.g., a bag or bottle for intravenous administration). The kit may also include a fluid conduit with a drip chamber, such as a plastic tube. The drip chamber may be communicated with the intravenous needle through the fluid conduit. The fluid conduit may also include one or more Y-shaped sites and a rolling clamp. Example
[0165] Abbreviations: CAR (chimeric antigen receptor); CF (citrullinated fibrinogen); CFSE (carboxyfluorescein succinimidyl ester); CV (citrullinated vimentin); EGFR (epidermal growth factor receptor); IN (intranasal); IV (intravenous); LPS (lipopolysaccharide); PAD2 (peptidyl arginine deiminase 2); PBMC (peripheral blood mononuclear cells); PBS (phosphate buffered saline); RA (rheumatoid arthritis); scFv (single chain variable fragment); SF (synovial fluid); Teff (effector T cells); Treg (regulatory T cells); and UTD (untransduced). Example 1: SBT01G consistently performs as well or better than BVCA1 in the luciferase system
[0166] Jurkat-FF-Luciferase transduction - Plate 50,000 cells per well in RPMI with 2X protamine sulfate in each of 2 flat-bottom 96-well plates. Dilute the virus in RPMI so that the MOI of 100 μl is approximately 1. Then add 100 μl to one column on each 96-well plate. The plates are then rotated and placed in the incubator. The samples are combined the next day. The transduced cells are resuspended in culture medium and 100 μl is transferred to a U-bottom plate in duplicate. The cells are stained with CV-AF488 and CV-AF647 with 1:100 anti-EGFR-PE for 20 min at 4°C, washed once, and then analyzed by Novocyte. The samples are then scaled up to 6-well plates by adding 3 ml of fresh culture medium.
[0167] Plate Coating - First dilute citrullinated vimentin (CV) 1:100 into 4 ml PBS. Make five 4-fold serial dilutions by transferring 1 ml into 3 ml. Then add 100 μl to a 96-well plate. Place the plate at 4°C to coat overnight.
[0168] Luciferase Assay - Standardized transduced cells were pelleted and resuspended in 1 ml RPMI. CV coated plates were washed three times with PBS. 50 μl of cells were added to the plate. 25 μl of 3X PMA / Iono was added and the plate was placed in a 37°C incubator. After approximately 24 hours, the luciferase plate was read by adding 75 μl BioGlo reagent, incubating in the dark for 2-3 min and reading the plate.
[0169] Figure 1 Shown are the responses of virally transduced Jurkat-FF-luciferase cells to plates coated with different concentrations of full CV. The results show that BVCA1 and STB01 had the strongest responses to plate-bound full-length CV.
[0170] Figure 2Shown are the responses of virally transduced Jurkat-FF-luciferase cells to different concentrations of soluble CV. The results show that only BVCA1 and SBT01G-HL had a dose-dependent response to soluble full-length CV.
[0171] Figure 3 It is shown that BVCA1 and SBT01 exhibit binding specificity to CV in assays with soluble bead-bound peptides.
[0172] Figure 4 The responses of BVCA1 and SBT01G to plate-bound CV, antibody (V9)-captured CV, and soluble CV at different protein concentrations are shown. The results show that SBT01G has a stronger response to plate-bound CV and antibody (V9)-captured CV (but not soluble CV) than BVCA1. Example 2: SBT01 and BVCA1 respond to synovial fluid from patients with rheumatoid arthritis
[0173] Jurkat-FF-luciferase transduction - 24×10 6 Jurkat-FF-luc cells were precipitated and resuspended in 24 ml RPMI containing protamine sulfate and virus (MOI of 3) to express the CAR of pSB_0147, pSB-0149 and pSB0139. The cells were mixed and 4 ml was aliquoted into each well of a 6-well plate. The plate was then rotated and placed in an incubator overnight. The cells were precipitated and re-seeded in 25 ml RPMT in a T75 flask.
[0174] Synovial fluid stimulation - transduced cells were pelleted and resuspended in RPMI and placed in wells of black / white plates. Synovial fluid (SF) samples from RA patients were thawed, vortexed and diluted in RPMI and then added to the plates containing transduced cells. Cells were cultured with SF at 37°C.
[0175] Luciferase Assay - Approximately 24 hours later, 75 μl of BioGlo reagent was added to each well and the plate was incubated in the dark for 2-3 min. Luminescence was then read on a plate reader.
[0176] Treg separation and tissue culture-primary human Treg cells are derived from healthy donors, from leukocyte reduction chamber residues or enriched leukocyte apheresis products (leukopaks). Peripheral blood mononuclear cells (PBMC) are separated by density gradient centrifugation using Ficoll-Paque Plus. CD25+ cells are enriched by positive selection. Next, FACS is used to separate Treg cells by gating CD4+CD25+CD127lo cells. After separation, cells are stimulated with a 1:1 bead to cell ratio using CTSDynabeads Treg Xpander (Gibco), and cultured with recombinant human IL-2 (300IU / mL) at a density of 250,000-300,000 cells / mL in RPMI culture medium supplemented with 10% FBS, non-essential amino acids, sodium pyruvate and β-mercaptoethanol. On the 9th day of amplification, fresh CTSDynabeads Treg Xpander is added with a 1:1 bead to cell ratio.
[0177] Primary Treg Transduction - Primary Tregs were transduced with CV-CAR constructs via spin-occulation on day 2 of expansion in the presence of protamine sulfate.
[0178] Treg Activation - Treg cells expressing CV-CAR were cultured in vitro with synovial fluid sample dilutions ranging from 1:5 to 1:160. Treg activation was assessed by measuring CD71 expression.
[0179] Flow cytometry and FACS analysis - The activated cultures were collected and centrifuged at 300 × g for 5 min and then resuspended in 1X flow staining buffer (Invitrogen) with viability dye (Invitrogen), anti-EGFR and CD71 surface staining antibodies. Tregs were incubated at 4°C for 30 min, then centrifuged and washed with 1X flow staining buffer. The stained cells were fixed with CytoFix (BD Biosciences) and then analyzed by flow cytometry.
[0180] Figure 5 Shown are the responses of SBT01G and BVCA1 to synovial fluid from RA patients. The data show that SBT01G produced a stronger response to synovial fluid from several RA patients than BVCA1.
[0181] Figure 6 It is shown that for the synovial fluid samples from Swedish RA patients triggering the response, SBT01G is again stronger than BVCA1.
[0182] Figure 7The response of primary Treg cells transduced with CV-CAR to synovial fluid from multiple RA patients is shown. Primary Treg cells expressing SBT01G CAR are more sensitive to synovial fluid from RA patients than primary Treg cells expressing BVCA1 CAR. Example 3: Response of SBT01 and BVCA1 to citrullinated fibrinogen
[0183] Plate Coating - Citrullinated proteins were diluted in PBS and added to the wells of black / white isoplates. Plates were placed at 4°C overnight to coat the wells.
[0184] Luciferase Assay - Stably transduced and untransduced (UTD) Jurkat-FF-luc cell lines were pelleted and resuspended in RPMI containing 10% FBS. The citrullinated protein coated plates were washed three times with PBS. 50,000 cells / well in 75 μl were added to the coated plates. 5 μl of 15X PMA / Iono in RPMI was added to each well and the plates were placed in a 37°C incubator. After approximately 24 hours, 75 μl of BioGlo reagent was added to each well and the plates were incubated in the dark for 2-3 min. The luminescence was then read on a plate reader.
[0185] Treg separation and tissue culture-primary human Treg cells are derived from healthy donors, from leukopenia chamber residues or enriched leukocyte apheresis products. Peripheral blood mononuclear cells (PBMC) are separated by density gradient centrifugation using Ficoll-Paque Plus. CD25+ cells are enriched by positive selection. Next, FACS is used to separate Treg cells by gating CD4+CD25+CD127lo cells, and FACS is used to separate Teff by gating CD4+CD25loCD127pos. After separation, cells are stimulated with a 1:1 bead to cell ratio with CTSDynabeads Treg Xpander (Gibco) and cultured with recombinant human IL-2 (300IU / mL) at a density of 250,000-300,000 cells / mL in RPMI culture medium supplemented with 10% FBS, non-essential amino acids, sodium pyruvate and b-mercaptoethanol. On the 9th day of amplification, fresh CTSDynabeads Treg Xpander is added with a 1:1 bead to cell ratio.
[0186] Primary Treg and Teff transduction - Primary Treg and Teff were transduced with CD19-CAR and CV-CAR constructs via spin-occulation on day 2 of expansion in the presence of protamine sulfate.
[0187] Treg activation - Before the activation culture was started, CAR-expressing Tregs and Teffs were labeled with the proliferation dye CFSE. Treg cells expressing CD19-CAR and CV-CAR were cultured in vitro with plate-coated citrullinated vimentin (CV) or citrullinated fibrinogen (CF) at doses ranging from 30ng / ml to 10μg / ml. Treg activation was assessed by measuring the percentage of proliferating cells and by CD71 expression.
[0188] Flow cytometry and FACS analysis - The activated cultures were collected and centrifuged at 300 × g for 5 min and then resuspended in 1X flow staining buffer (Invitrogen) with viability dye (Invitrogen), anti-EGFR and CD71 surface staining antibodies. Tregs were incubated at 4°C for 30 min, then centrifuged and washed with 1X flow staining buffer. The stained cells were fixed with CytoFix (BD Biosciences) and then analyzed by flow cytometry.
[0189] Figure 8 Shown are the responses of SBT01G and BVCA1 to plate-bound full-length peptidylarginine deiminase 2 (PAD2)-citrullinated fibrinogen. The results show that SBT01G, but not BVCA1, is also able to respond to plate-bound full-length PAD2-citrullinated fibrinogen.
[0190] Fig. 9 It is shown that the SBT01G CAR expressed on Teff cells and Treg cells responds to citrullinated vimentin (CV) and citrullinated fibrinogen (CF). In contrast, the BVCA1 CAR expressed on Teff cells and Treg cells responds to CV but not CF.
[0191] therefore, Figure 1-Figure 9 It was shown that SBT01G consistently performed as well as or better than BVCA1 in all assay systems. Example 4: CV CARS exhibits functional responses when using different promoters and linkers
[0192] Treg separation and tissue culture-primary human Treg cells are derived from healthy donors, from leukopenia chamber residues or enriched leukocyte apheresis products. Peripheral blood mononuclear cells (PBMC) are separated by density gradient centrifugation using Ficoll-Paque Plus. CD25+ cells are enriched by positive selection. Next, FACS is used to separate Treg cells by gating CD4+CD25+CD127lo cells. After separation, cells are stimulated with CTSDynabeads Treg Xpander (Gibco) at a bead to cell ratio of 1: 1, and cultured with recombinant human IL-2 (300IU / mL) at a density of 250,000-300,000 cells / mL in RPMI culture medium supplemented with 10% FBS, non-essential amino acids, sodium pyruvate and b-mercaptoethanol. On the 9th day of amplification, fresh CTSDynabeads Treg Xpander is added with a bead to cell ratio of 1: 1.
[0193] Primary Treg Transduction - Primary Tregs were transduced with CV-CAR constructs via spin-occulation on day 2 of expansion in the presence of protamine sulfate.
[0194] Treg Activation - Prior to the start of activation cultures, CAR-expressing Tregs were labeled with the proliferation dye CFSE. Treg cells expressing CV-CAR were cultured in vitro with bead-captured CV peptides. Treg activation was assessed by measuring the percentage of proliferating cells.
[0195] Flow cytometry and FACS analysis Activation assay - Activated cultures were collected and centrifuged at 300 × g for 5 min and then resuspended in 1X flow staining buffer (Invitrogen) with viability dye (Invitrogen) and anti-EGFR surface staining antibody. Tregs were incubated at 4°C for 30 min and then centrifuged and washed with 1X flow staining buffer. The stained cells were fixed with CytoFix (BD Biosciences) and then analyzed by flow cytometry.
[0196] Flow cytometry and FACS analysis of Treg phenotype - Tregs expressing CD19-CAR and CV-CAR were stained for transcription factors FoxP3 and Helios at day 14 of expansion of untransduced (UTD) cells. Cells were fixed and permeabilized using the eBiosciences FoxP3 transcription factor buffer kit (eBiosciences).
[0197] Treg culture resting - On day 14 of expansion, Tregs expressing CD19-CAR and CV-CAR were harvested, de-beaded using a magnet, and cultured at 500,000 cells / ml with 300 IU / ml IL-2 alone.
[0198] CAR expression flow cytometry and FACS analysis - CD19-CAR and CV-CAR expressing Tregs were stained with viability dye (Invitrogen) and anti-EGFR surface staining antibody at day 14 of expansion and after 2 or 5 days of rest. CV-CAR expression was detected by incubating cells with 1 μg / ml CV and then with FITC-labeled anti-vimentin (clone V9, Invitrogen).
[0199] Plate Coating - Citrullinated Vimentin (CV) was diluted in PBS and added to the wells of the black / white isoplate. The plates were placed at 4°C overnight to coat the wells.
[0200] Luciferase Assay - Stably transduced and untransduced (UTD) Jurkat-FF-luc cell lines were pelleted and resuspended in RPMI containing 10% FBS. The citrullinated protein coated plates were washed three times with PBS. 50,000 cells / well in 75 μl were added to the coated plates. 5 μl of 15X PMA / Iono in RPMI was added to each well and the plates were placed in a 37°C incubator. After approximately 24 hours, 75 μl of BioGlo reagent was added to each well and the plates were incubated in the dark for 2-3 min. The luminescence was then read on a plate reader.
[0201] Fig. 10A It was shown that both EF1A and MND promoters drive expression of CV-CAR T cells and functional responses to soluble bead-bound citrullinated peptide (pCV). Fig. 10B It was shown that using different promoters did not change the phenotype of CV-CAR Treg cells.
[0202] Fig.11 It was shown that the choice of scFv linker had little impact on the response of SBT01G CAR T cells to full-length CV.
[0203] Fig. 12A It is shown that transduction with the SBT01G CAR vector resulted in CV-CAR expression in a higher percentage of cells compared to transduction with the BVCA1 CAR vector. Fig. 12B It was shown that SBT01G CAR and BVCA1CAR Treg cells have similar FoxP3 and Helios signatures.
[0204] Therefore, Figures 10 to 12 show that SBT01G showed a higher percentage of CAR-positive Tregs, and SBT01G showed a higher level of CAR expression. Example 5: In vitro evaluation of citrullinated vimentin activation of CV-CAR Tregs
[0205] Treg separation and tissue culture-primary human Treg cells are derived from healthy donors, from leukocyte reduction chamber residues or enriched leukocyte apheresis products. Peripheral blood mononuclear cells (PBMC) are separated by density gradient centrifugation using Ficoll-Paque Plus. CD25+ cells are enriched by positive selection. Next, FACS is used to separate Treg cells by gating CD4+CD25+CD127lo cells. After separation, cells are stimulated with CTSDynabeads Treg Xpander (Gibco) with a bead to cell ratio of 1: 1 and cultured with recombinant human IL-2 (300IU / mL) at a density of 250,000-300,000 cells / mL in RPMI medium supplemented with 10% FBS, non-essential amino acids, sodium pyruvate and penicillin / streptomycin.
[0206] Treg Activation-Untransduced and CV-CAR-expressing Treg cells were cultured in vitro with doses ranging from 10 ng / mL to 10 μg / mL of citrullinated vimentin antigen. Treg activation was assessed by measuring the percentage of proliferating cells and the levels of CD71 expression and IL-10 secretion.
[0207] Flow cytometry and FACS analysis: Untransduced and CV-CAR-expressing Treg cells were collected and centrifuged at 300 × g for 5 min, then resuspended in 1X RoboSep buffer (StemCell Technologies) with CD71 surface staining antibody and Cell Trace Violet (CTV) viability dye mixture (Invitrogen). Tregs were incubated at 4 ° C for 30 min, then centrifuged and washed with 1X RoboSep buffer. The stained cells were then analyzed by flow cytometry. result
[0208] Treg activation in response to citrullinated vimentin (CV) was assessed in vitro. Fig.13 Dose-dependent, CV-induced activation of CV-CAR Treg cells is shown, as shown by the increase in proliferating cells, CD71 expression and IL-10 secretion. In contrast, untransduced Treg cells are not activated by CV. These results demonstrate that Treg activation after CV stimulation is unique to Treg expressing CV-CAR.
[0209] The amount of CV present in the synovial fluid of healthy donors and rheumatoid arthritis (RA) patients was assessed by ELISA. Fig.14 Jurkat reporter cells expressing one of three different CV-CARs or a control CD19-CAR were incubated with increasing amounts of synovial fluid, and the response was measured as an indicator of signaling for CV-CAR binding and T cell activation. Fig.14 It is shown that Jurkat cells (immortalized human T lymphocytes) expressing CV-CAR1 (BVCA1) and CV-CAR2 (SBT01G), but not CV-CAR3 (C03) or CD19-CAR, showed an increased response to synovial fluid (SF). Fig.14 It was also shown that SF samples from more RA patients activated CV-CAR2 (SBT01G) T cells compared to CV-CAR1 (BVCA1) T cells.
[0210] To demonstrate that CV-CAR-expressing Tregs were activated by citrullinated antigens in the synovial fluid of RA patients, untransduced and CV-CAR2 Tregs were incubated with RA synovial fluid or vehicle, and the levels of proliferation and CD71 expression were measured. Fig.15 It was shown that CV-CAR2 Treg cells from two donors were activated in an RA synovial fluid-specific manner.
[0211] Together, these results demonstrate that CV-CAR Treg cells are able to bind citrullinated antigens present in RA synovial fluid, leading to activation essential for suppressive function. Example 6: Evaluation of CV-induced suppression of Teff cells by CV-CAR Treg
[0212] Treg suppression assay-As described above, Treg cells expressing CV-CAR were prepared from fresh people through enrichment of leukocyte apheresis products in 96-well U-bottom plates. Tregs were incubated with CV as antigen stimulators or with vehicle controls. Tregs were co-cultured with CD3 / CD28 activated or CD19-CAR specific Teff cells to assess Treg inhibition of target cells. Teff cells were co-cultured at the following Treg:Teff ratios: (CD3 / CD28 activation) 1:4=0.25, 1:2=0.5, 1:1=1, 2:1=2, and 4:1=4, or (CD19 specific) 1:4, 1:2, 1:1, 2:1, and 4:1. result
[0213] Fig.16A It was shown that CV-CAR Tregs stimulated with CV were able to inhibit the proliferation of CD3 / CD28 activated Teff cells at low Treg:Teff ratios. Fig. 16B It was shown that CV-CAR Tregs stimulated with CV were able to inhibit the proliferation of CD19-CAR Teff cells at low Treg:Teff ratios. Example 7: Analysis of CV-CAR Tregs in a rodent model of CV-related lung inflammation
[0214] In human rheumatoid arthritis (RA) patients, the consistently high concentration of citrullinated vimentin (CV) in the synovial fluid makes CV identified as a relevant biomarker for human RA. However, the RA mouse model of the present invention shows inconsistent CV levels, which complicates the in vivo analysis of CV-CAR Treg. In order to induce CV production and release into the extracellular matrix, a mouse model of LPS-induced lung inflammation was developed. The model is characterized by an acute inflammatory response within a few days after intranasal LPS stimulation, including increased secretion of pulmonary neutrophils and proinflammatory cytokines interleukin-6 (IL-6), interleukin-1β (IL-1b) and tumor necrosis factor-α (TNF-α), as well as CV accumulation in lung tissue. It has been shown that chimeric antigen receptors (CARs) specific for CV react with accumulated CV proteins in lung tissue, which results in increased survival, proliferation, and inhibitory activity of corresponding CV-CAR Treg cells in an antigen-specific manner. method
[0215] Six to eight-week-old immunocompromised NCG mice were obtained from Charles River Laboratories. Mice were randomized by body weight and divided into groups of 5-10 animals. On days 0, 1, 6, and 12, mice were treated intranasally (IN) with LPS (5 mg / kg) to induce lung inflammation and release and accumulate citrullinated vimentin (CV) in affected tissues. On day 0, CV-CAR Treg cells were harvested from actively growing cultures, the stimulating beads were removed magnetically, and Tregs were subsequently labeled with Cell Trace Violet (CTV) (Invitrogen). Approximately 4 hours after the initial LPS stimulation, CTV-labeled Tregs were adjusted to 25 x 10 in 0.9% sterile saline solution (NaCl). 6 cells / mL and injected intravenously (IV) in 200 μl doses so that each mouse received a total of 5 x 10 6Cells. After CV-CAR Treg or control CD19-CAR Treg adoptive cell transfer, all mice received intraperitoneal (IP) injections of IL-2 (160,000 IU) on days 1, 2, 5, 6, 7, 8, 9, and 12. Mice were monitored daily for any clinical signs of illness and body weight was measured twice a week. Mice were euthanized on day 13, and spleens and lungs were harvested and processed into single cell suspensions for flow cytometric analysis of human CV-CAR and CD19-CAR Treg. result
[0216] Fig.17 An exemplary timeline for induction of CV-associated lung inflammation and in vivo activation of CV-CAR Treg cells in mice is shown. result
[0217] Fig.18A shows how to calculate proliferation rate from flow cytometry data, and Fig.18B Shown is how the fold change of EGFR ratio (CAR marker) was calculated from the same data.
[0218] Fig.19A It was shown that the absolute number of CV-CAR Tregs was significantly enriched in lung tissues from mice with LPS-induced lung inflammation. Fig.19B It was shown that the proliferation rate of CV-CAR Tregs was significantly increased in lung tissue from mice with LPS-induced lung inflammation. These results demonstrate that CV-CAR Tregs have an improved ability to home in and proliferate in inflamed lung tissue characterized by accumulation of citrullinated vimentin compared to control Tregs. Therefore, this murine lung inflammation model allows for in vivo testing of human CV-CAR Tregs. Exemplary embodiments 1. A chimeric antigen receptor (CAR), comprising an antigen binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains and an intracellular signaling domain, wherein the antigen binding domain specifically binds to a citrullinated polypeptide, optionally wherein the antigen binding domain specifically binds to three or more different citrullinated proteins or citrullinated fragments thereof. 2. The CAR according to embodiment 1, wherein the antigen binding domain binds to a plurality of different citrullinated proteins or citrullinated fragments thereof. 3. A CAR according to embodiment 1, wherein the antigen binding domain binds to one or more of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, (iii) citrullinated fibrinogen, and (iv) citrullinated peptide fragments of these, such as fragments having at least any one of 10, 12, 14 or 16 amino acids. 4. The CAR according to embodiment 1, wherein the antigen binding domain binds to at least two of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, and (iii) citrullinated fibrinogen, or citrullinated peptide fragments thereof. 5. The CAR according to embodiment 1, wherein the antigen binding domain binds to all three of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, and (iii) citrullinated fibrinogen, or citrullinated peptide fragments thereof. 6. According to the CAR of embodiment 5, the CAR further binds to citrullinated tenascin C. 7. The CAR according to embodiment 1, wherein the antigen binding domain comprises a VH domain and a VL domain, wherein: (i) the VH domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO: 32, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 36, and (ii) the VL domain of the target binding domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:39, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:43. 8. The CAR according to embodiment 1, wherein the intracellular signaling domain is derived from CD3ζ. 9. According to the CAR of embodiment 1, the at least one co-stimulatory domain is derived from a member of the group consisting of: FceR1g, Fcg, CD28, 4-1BB, CTLA-4, CTLA-4 / CD-28 hybrid, DAP10, CD27 and 2B4, optionally wherein the at least one co-stimulatory domain includes CD28 and / or 4-1BB co-stimulatory domains. 10. The CAR according to embodiment 1, wherein the antigen binding domain comprises an antibody, an antibody fragment, a camelid nanobody, a heavy chain-only antibody, or an aptamer. 11. A CAR according to any one of embodiments 1 to 10, wherein the transmembrane domain is a CD8 transmembrane domain or a CD28 transmembrane domain; and the hinge domain is a CD8 hinge domain or a CD28 hinge domain; and / or further comprises a signal peptide, optionally wherein the signal peptide is a CD8 signal peptide or a GM-CSF signal peptide. 12. The CAR according to embodiment 11, wherein the antigen-specific binding domain comprises a single-chain fragment. 13. The CAR of embodiment 12, wherein the single-chain fragment comprises a single-chain variable fragment (scFv), optionally wherein the scFv fragment comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 1; and (b) A VL domain comprising the amino acid sequence of SEQ ID NO:4. 14. The CAR according to embodiment 13, wherein the scFv fragment comprises: (a) a VH selected from the following: (1)SBT01 VH(M) or (2) SBT01 VH(G) and (b) a VL selected from the following: (1)SBT01 VL(M) or (2)SBT01 VL(G) 15. The CAR according to embodiment 14, wherein the VH-VL fragments are connected by a linker selected from the group consisting of: (i) GGGSx3 (SEQ ID NO: 20), (ii) Whitlow 218 (SEQ ID NO: 21), and (iii) AB Pur (SEQ ID NO: 22). 16. The CAR according to embodiment 13, wherein the scFv comprises the following amino acid sequence: (a) SBT01G-VHVL-GGGSx3 linker-pSB_0149 (GGGSx3 connector is underlined); or (b) SBT01G-VHVL-Whitlow 218 adapter-pSB_0158 (Whitlow 218 connector is underlined); or (c) SBT01G-VHVL-AB pur linker-pSB_0159 (AB pur linker is underlined). 17. A CAR according to any one of embodiments 1-16, wherein the co-stimulatory domain comprises a CD28, 41BB, OX40, OX40, CD40L, MyD88, CD40, CD27, ICOS or RANK / TRANCE-R co-stimulatory domain. 18. A nucleic acid encoding a CAR according to any one of embodiments 1-17. 19. The nucleic acid of embodiment 18, wherein the nucleic acid comprises DNA or RNA. 20. The nucleic acid according to embodiment 18, wherein The VH is encoded by a nucleic acid sequence comprising: or and The VL is encoded by a nucleic acid sequence comprising: or 21. The nucleic acid of embodiment 20, wherein the VH and VL fragments are connected by a linker and comprise the nucleic acid sequence of (i) SEQ ID NO: 12, (ii) SEQ ID NO: 13, or (iii) SEQ ID NO: 14. 22. An expression vector comprising an expression control sequence operably linked to the nucleic acid sequence of any one of embodiments 16-21. 23. An expression vector according to embodiment 22, wherein the expression control sequence comprises a regulatory region, wherein the regulatory region is selected from: a promoter sequence, an enhancer sequence, a response element, a protein recognition site, an inducible element, a protein binding sequence, a 5' and 3' untranslated region, a transcription start site, a termination sequence, a polyadenylation sequence, a nuclear localization, a signal and an intron. 24. An expression vector according to embodiment 23, wherein the vector is an adenoviral vector, a lentiviral vector or a plasmid. 25. A host cell comprising the expression vector according to embodiment 22, 23 or 24. 26. A modified T cell, which has been modified to express a chimeric antigen receptor (CAR) according to any one of embodiments 1-17. 27. The modified T cell of embodiment 26, wherein the T cell is a mammalian T cell. 28. The modified T cell of embodiment 27, wherein the T cell is a Treg cell. 29. The modified T cell of embodiment 28, wherein the T cell is a human T cell. 30. The modified T cell of embodiment 29, wherein the T cell is a primary T cell. 31. The modified T cell of embodiment 30, wherein the T cell is CD4+, CD25+ and CD127lo. 32. A pharmaceutical composition comprising a plurality of modified T cells according to any one of embodiments 26 to 31 and a pharmaceutically acceptable carrier. 33. A method of treating a subject suffering from rheumatoid arthritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition according to embodiment 32. 34. A method according to embodiment 33, wherein the subject is human. 35. The method of embodiment 33 or 34, wherein the pharmaceutical composition is administered into the synovium of the subject. 36. The method of embodiment 33 or 34, wherein the pharmaceutical composition is administered intravenously. 37A. The method of embodiment 33, wherein administering comprises: (a) isolating T cells from a biological sample obtained from the subject; (b) enriching regulatory T cells (Tregs) in the T cells; (c) transfecting the enriched Treg cells with an expression vector, wherein the expression vector comprises an expression control sequence operably linked to a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises comprising an antigen binding domain that binds a citrullinated polypeptide; (d) expanding the transfected Treg cells; and (e) administering the expanded Treg cells to the subject. 37B. A method of treating a subject suffering from rheumatoid arthritis, the method comprising: (a) isolating T cells from a biological sample obtained from the subject; (b) enriching regulatory T cells (Tregs) in the T cells; (c) transfecting the enriched cell with an expression vector encoding the CAR according to any one of embodiments 1-17 Collection of Treg cells; (d) expanding the transfected Treg cells; and (e) administering the expanded Treg cells to the subject. 38. A method according to embodiment 37, wherein the amplification includes the use of anti-CD3 / CD28 coated beads. 39. A method according to embodiment 37, wherein the amplification does not use anti-CD3 / CD28 coated beads. 40. The method according to embodiment 37, wherein the transfection is performed by using viral vectors, electroporation, heat shock, phage, sonication or calcium phosphate. 41. The method of any one of embodiments 37 to 40, further comprising administering one or more anti-inflammatory and / or therapeutic agents to the subject. 42. A method according to embodiment 41, wherein the anti-inflammatory agent comprises an antibody that inhibits pro-inflammatory cytokines 43. A method according to embodiment 42, wherein the anti-inflammatory agent is an anti-TNF antibody, an anti-IL-6 antibody, or a combination thereof. 44. A kit comprising a container containing the pharmaceutical composition according to embodiment 32, wherein the container is connected to a drip chamber through a fluid conduit, wherein the drip chamber is connected to a venous needle through a fluid conduit. 45. The kit of embodiment 44, wherein the container comprises a bag. 46. A kit according to embodiment 44, wherein the fluid conduit between the container and the needle includes one or more Y-sites and roller clamps.
[0219] It should be understood that the description and the drawings are not intended to limit the present invention to the specific form disclosed, but on the contrary, the present invention covers all modifications, equivalents and substitutes falling within the spirit and scope of the present invention as defined by the appended claims. In view of this description, further modifications and alternative embodiments of various aspects of the present invention will be clear to those skilled in the art. Therefore, this description and the drawings are to be understood as illustrative only, and are intended to teach those skilled in the art the general manner of implementing the present invention. It should be understood that the forms of the present invention shown and described herein will be regarded as examples of embodiments. Elements and materials may replace the elements and materials shown and described herein, parts and processes may be reversed or omitted, and certain features of the present invention may be used independently, all of which are as clear to those skilled in the art after benefiting from this description of the present invention. Without departing from the spirit and scope of the present invention as described in the following claims, the elements described herein may be changed. The titles used herein are for organizational purposes only and are not intended to be used to limit the scope of this specification.
[0220] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0221] In summary, the present invention includes but is not limited to the following: 1. A chimeric antigen receptor (CAR), comprising an antigen binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains and an intracellular signaling domain, wherein the antigen binding domain specifically binds to three or more different citrullinated proteins or citrullinated fragments thereof. 2. A CAR according to claim 1, wherein the antigen binding domain binds to all three of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, and (iii) citrullinated fibrinogen, or citrullinated peptide fragments thereof. 3. A CAR according to item 2, wherein the antigen binding domain further binds to citrullinated tenascin C. 4. The CAR according to item 1, wherein the antigen binding domain comprises a VH domain and a VL domain, wherein: (i) the VH domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO: 32, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 36, and (ii) the VL domain of the target binding domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:39, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:43. 5. A CAR according to item 1, wherein the intracellular signaling domain is derived from CD3-ζ. 6. A CAR according to item 1, wherein the at least one co-stimulatory domain comprises a co-stimulatory domain of a member of the group consisting of: FceR1g, Fcg, CD28, CD134 (OX40), CD137 (4-1BB), CTLA-4, CTLA-4 / CD-28 hybrid, DAP10, CD27, 2B4 and combinations thereof, optionally wherein the at least one co-stimulatory domain comprises a CD28 and / or 4-1BB co-stimulatory domain. 7. A CAR according to item 1, wherein the antigen binding domain comprises an antibody, an antibody fragment, a camelid nanobody, a heavy chain-only antibody, or an aptamer. 8. A CAR according to item 1, wherein the transmembrane domain is a CD8 transmembrane domain or a CD28 transmembrane domain. 9. A CAR according to item 1, wherein the hinge domain is a CD8 hinge domain or a CD28 hinge domain. 10. The CAR according to item 1, further comprising a signal peptide. 11. The CAR according to item 10, wherein the signal peptide is a CD8 signal peptide or a GM-CSF signal peptide. 12. A CAR according to item 1, wherein the antigen-specific binding domain comprises a single-chain fragment. 13. A CAR according to claim 12, wherein the single-chain fragment comprises a single-chain variable fragment (scFv). 14. The CAR according to item 13, wherein the scFv fragment comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 1; and (b) A VL domain comprising the amino acid sequence of SEQ ID NO:4. 15. The CAR according to item 13, wherein the scFv fragment comprises: (a) a VH selected from the following: (1)SBT01 VH(M) HLHLQESGPGLVKPSETLSLTCTVSGGSINDTTYYWGWIRQPPGKGLEWIGSI YYRGNTHYNSSLRSRVTMSVDTSKNRFSLKVTSVTAADTAVYYCARLDPFDYWGRGTLVTVSS(SEQID NO:1); or (2) SBT01 VH(G) QLQLQESGPGLVKPSETLSLTCTVSGGSISSSSYYWGWIRQPPGKGLEWIGSIY YSGSTYYNPSLKSRVTISSVDTSKNQFSLKLSSVTAADTAVYYCARLDPFDYWGRGTLVTVSS(SEQ IDNO:2); (b) a VL selected from the following: (1)SBT01 VL(M) SYVLTQPPSVSLAPGETATITCGGDDIENQNVNWYQQKSGQAPMLLIFFDTRR PSGIPERFSGSRSEDTANLTITRVEAGDDADYFCQVYDRKTDHQVFGPGTTVTVL(SEQ ID NO:3) or (2)SBT01 VL(G) SYVLTQPPSVSVVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVIYYDSD RPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHQVFGTGTKVTVL (SEQ ID NO: 4). 16. A CAR according to item 15, wherein the VH-VL fragments are connected by a linker selected from the group consisting of: (i) GGGSx3 (SEQ ID NO: 20), (ii) Whitlow 218 (SEQ ID NO: 21), and (iii) AB Pur (SEQ ID NO: 22). 17. The CAR according to item 16, wherein the scFv comprises the following amino acid sequence: (a) the SBT01G-VHVL-GGGSx3 linker of SEQ ID NO: 5; or (b) the SBT01G-VHVL-Whitlow 218 linker of SEQ ID NO: 6; or (c) SBT01G-VHVL-AB pur linker of SEQ ID NO:7. 18. A nucleic acid encoding a CAR according to any one of items 1-17. 19. The nucleic acid according to item 18, wherein the nucleic acid comprises DNA or RNA. 20. The nucleic acid according to item 18, wherein the VH is encoded by a nucleic acid sequence comprising SEQ ID NO: 8 or SEQ ID NO: 9; and the VL is encoded by a nucleic acid sequence comprising SEQ ID NO: 10 or SEQ ID NO: 11. 21. The nucleic acid according to item 20, wherein the VH and VL fragments are connected by a linker and comprise the nucleic acid sequence of SEQ ID NO: 12, or (ii) SEQ ID NO: 13, or (iii) SEQ ID NO: 14. 22. An expression vector comprising an expression control sequence operably linked to the nucleic acid sequence according to item 21. 23. An expression vector according to item 22, wherein the expression control sequence comprises a regulatory region, wherein the regulatory region is selected from: a promoter sequence, an enhancer sequence, a response element, a protein recognition site, an inducible element, a protein binding sequence, a 5' and 3' untranslated region, a transcription start site, a termination sequence, a polyadenylation sequence, a nuclear localization, a signal and an intron. 24. An expression vector according to item 23, wherein the vector is an adenoviral vector, a lentiviral vector or a plasmid. 25. A host cell comprising the expression vector according to item 24. 26. A modified T cell, which has been modified to express a chimeric antigen receptor (CAR) according to any one of items 1-17. 27. A modified T cell according to item 26, wherein the T cell is a mammalian T cell. 28. The modified T cell of claim 27, wherein the T cell is a Treg cell. 29. The modified T cell of claim 28, wherein the T cell is a human T cell. 30. The modified T cell of claim 29, wherein the T cell is a primary T cell. 31. The modified T cell of claim 30, wherein the T cell is CD4+, CD25+ and CD127lo. 32. A pharmaceutical composition comprising a plurality of modified T cells according to item 31 and a pharmaceutically acceptable carrier. 33. A method of treating a subject suffering from rheumatoid arthritis, the method comprising administering to the subject an effective amount of the pharmaceutical composition according to item 32. 34. A method according to claim 33, wherein the subject is a human. 35. A method according to claim 33, wherein the pharmaceutical composition is administered into the synovium of the subject. 36. A method according to claim 33, wherein the pharmaceutical composition is administered intravenously. 37. A method of treating a subject suffering from rheumatoid arthritis, the method comprising: (a) isolating T cells from a biological sample obtained from the subject; (b) enriching regulatory T cells (Tregs) in the T cells; (c) transfecting the enriched Treg cells with an expression vector encoding the CAR according to any one of items 1-17; (d) expanding the transfected Treg cells; and (e) administering the expanded Treg cells to the subject. 38. A method according to claim 37, wherein the amplification comprises the use of anti-CD3 / CD28 coated beads. 39. A method according to claim 37, wherein the amplification does not include the use of anti-CD3 / CD28 coated beads. 40. The method according to item 37, wherein the transfection is performed by using viral vectors, electroporation, heat shock, bacteriophage, sonication or calcium phosphate. 41. The method of claim 37, further comprising administering one or more anti-inflammatory agents and / or therapeutic agents to the subject. 42. A method according to claim 41, wherein the anti-inflammatory agent comprises an antibody that inhibits pro-inflammatory cytokines. 43. A method according to claim 42, wherein the anti-inflammatory agent is an anti-TNF antibody, an anti-IL-6 antibody, or a combination thereof. 44. A kit comprising a container containing the pharmaceutical composition according to item 32, wherein the container is connected to a drip chamber through a fluid conduit, wherein the drip chamber is connected to a venous needle through a fluid conduit. 45. A kit according to item 44, wherein the container comprises a bag. 46. A kit according to claim 44, wherein the fluid conduit between the container and the needle includes one or more Y-sites and roller clamps.
Claims
1. A chimeric antigen receptor (CAR), comprising an antigen binding domain, a hinge domain, a transmembrane domain, one or more co-stimulatory domains and an intracellular signaling domain, wherein the antigen binding domain specifically binds to three or more different citrullinated proteins or citrullinated fragments thereof, and the antigen domain comprises complementarity determining regions (CDRs) from VH and VL domains of SEQ ID NO: 1 and SEQ ID NO:
4.
2. The CAR of claim 1, wherein the antigen binding domain binds to all three of the following: (i) citrullinated vimentin, (ii) citrullinated filaggrin, and (iii) citrullinated fibrinogen, or citrullinated peptide fragments thereof.
3. The CAR of claim 1, wherein the antigen binding domain comprises a VH domain and a VL domain, wherein: (i) the VH domain comprises a VH-CDR1 comprising the amino acid sequence of SEQ ID NO: 32, a VH-CDR2 comprising the amino acid sequence of SEQ ID NO: 34, and a VH-CDR3 comprising the amino acid sequence of SEQ ID NO: 36, and (ii) the VL domain comprises a VL-CDR1 comprising the amino acid sequence of SEQ ID NO:39, a VL-CDR2 comprising the amino acid sequence of SEQ ID NO:41, and a VL-CDR3 comprising the amino acid sequence of SEQ ID NO:
43.
4. The CAR of claim 1, wherein the intracellular signaling domain is derived from CD3-ζ.
5. The CAR of claim 1, wherein the one or more co-stimulatory domains comprise domains of the group consisting of: FceR1g, Fcg, CD28, CD134 (OX40), CD137 (4-1BB), CTLA-4, CTLA-4 / CD-28 hybrid, DAP10, CD27, 2B4, and combinations thereof.
6. The CAR of claim 1, wherein the antigen binding domain comprises an antibody, an antibody fragment, a camelid nanobody, a heavy chain-only antibody, or an aptamer.
7. The CAR of claim 1, wherein the transmembrane domain is a CD8 transmembrane domain or a CD28 transmembrane domain.
8. The CAR of claim 1, wherein the hinge domain is a CD8 hinge domain or a CD28 hinge domain.
9. The CAR of claim 1, wherein the antigen-specific binding domain comprises a single-chain fragment.
10. The CAR of claim 9, wherein the single-chain fragment comprises a single-chain variable fragment (scFv).
11. The CAR of claim 10, wherein the scFv fragment comprises: (a) a VH domain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 1; and (b) a VL domain comprising an amino acid sequence that is at least 95% identical to SEQ ID NO:
4.
12. The CAR of claim 10, wherein the scFv fragment comprises: (a) a VH domain comprising the amino acid sequence of SEQ ID NO: 1; and (b) A VL domain comprising the amino acid sequence of SEQ ID NO:
4.
13. The CAR of claim 12, wherein the VH domain and the VL domain are connected by a linker comprising an amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 21 or SEQ ID NO:
22.
14. The CAR of claim 13, wherein the scFv fragment comprises the amino acid sequence of SEQ ID NO:
5.
15. A nucleic acid encoding the CAR according to any one of claims 1-14.
16. The nucleic acid of claim 15, wherein the VH domain is encoded by a nucleic acid sequence comprising SEQ ID NO:8; and the VL domain is encoded by a nucleic acid sequence comprising SEQ ID NO:
11.
17. The nucleic acid of claim 16, wherein the VH and VL fragments are connected by a linker and comprise the nucleic acid sequence of SEQ ID NO: 12, or (ii) SEQ ID NO: 13, or (iii) SEQ ID NO:
14.
18. An expression vector comprising an expression control sequence operably linked to the nucleic acid sequence according to claim 17.
19. A modified T cell, which has been modified to express a chimeric antigen receptor (CAR) according to any one of claims 1-14.
20. The modified T cell of claim 19, wherein the T cell is a regulatory T (Treg) cell.
21. The modified T cell of claim 20, wherein the T cell is a human T cell.
22. The modified T cell of claim 21, wherein the T cell is a primary T cell.
23. The modified T cell of claim 22, wherein the T cell is CD4+, CD25+ and CD127lo.
24. A pharmaceutical composition comprising a plurality of modified T cells according to claim 23 and a pharmaceutically acceptable carrier.
25. Use of the pharmaceutical composition according to claim 24 in the preparation of a medicament for treating rheumatoid arthritis.
26. The use according to claim 25, wherein the pharmaceutical composition is formulated for administration into the synovium of a subject.
27. The use according to claim 25, wherein the pharmaceutical composition is formulated for intravenous administration to a subject.
28. A method comprising: (a) Enrichment of T cells from a biorepository of regulatory T (Treg) cells; (b) transfecting the enriched Treg cells with an expression vector encoding the CAR according to any one of claims 1-14; and (c) expanding the transfected Treg cells.
29. The method of claim 28, wherein the amplification comprises the use of anti-CD3 / CD28 coated beads.
30. The method of claim 28, wherein the amplification does not comprise the use of anti-CD3 / CD28 coated beads.
